**CHRISTY A. RUSSELL, M.D**.

**CURRICULUM VITAE**

**A. Personal Information:**

Name in Full Christy Ann Russell, M.D.

Business Address Exact Sciences/Genomic Health

101 Galveston Drive

Redwood City, CA 94063

Business Phone (650) 599-4394

Work Email CRussell@exactsciences.com

Home Fax (626) 791-9021

Citizenship USA

**B. Education:**

University University of Pittsburgh

Pittsburgh, Pennsylvania

B.S., 1976

Medical School Medical College of Pennsylvania Philadelphia, Pennsylvania

Doctorate of Medicine, 1980

Residency Good Samaritan Medical Center and

Phoenix Veteran’s Hospital

Phoenix, Arizona

Internal Medicine

July 1980-June 1983

Fellowship LAC/USC Medical Center

Los Angeles, California

Hematology / Medical Oncology

July 1983-June 1986

Licensure California, 1983 Active

Board Certification American Board of Internal Medicine, 1983

American Board of Medical Oncology, 1985

Honors and Awards Wellness Community-Foothill Branch Angel Award 2000

AstraZeneca Oncology: Visions of Hope Award - 2003

YWCA Pasadena: Woman of Excellence in the Field of Medicine - 2004

Women of Courage Award: ABC7 Award Los Angeles, CA, 2006

**C. Professional Experience:**

**Employment:**

Senior Medical Director US Medical Affairs, Genomic Health, Inc. Redwood City, CA. 2017-2021

**Vice President US Medical Affairs, Precision Oncology, Exact Sciences. Redwood City, CA. 2021 – present**

**Academic Appointments**

**Associate Professor of Medicine, University of Southern California, Department of Medicine, Los Angeles, CA, 1998-2017**

Assistant Professor of Medicine, University of Southern California, Department of Medicine, Los Angeles, CA, 1986 - 1998.

Chief, USC/Norris Comprehensive Cancer Center, Division of Medicine, Los Angeles, CA, 1997-2001

Director, Medical Oncology Fellowship Program, Los Angeles County Medical Center, Los Angeles, CA 1991-2008

**Clinical Administrative Appointments**

**Medical Director, Utilization Review, Norris Breast Center, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, 2008 – 2017**

**Co-Director, Norris Breast Center, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, 1997-2017**

Associate Director, Norris Breast Center, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, Los Angeles, CA, 1993-1997

Chief of Staff, Norris Breast Center, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, 1994-1996

Vice Chief of Staff, Norris Breast Center, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, 1992-1994

Sect./Treas of Staff, Norris Breast Center, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, 1990-1992

**University Committees**

Keck School of Medicine Faculty Council, 2012-2015

Member, Board of Directors, Norris Breast Center, NCCC, Los Angeles, CA, 1994-1996

Member, Marketing and Planning Committee, NCCC, Los Angeles, CA, 1992-1996

Chairman, Ambulatory Care Committee, Norris Breast Center, NCCC, Los Angeles, CA, 1991-1996

Medical Director, Employee Health, Norris Breast Center, NCCC, Los Angeles, CA, 1988-2002

Member, Norris Leadership Council, Norris Breast Center, NCCC, Los Angeles, CA, 1996-2001 2016-2017

Member, Medical Executive Committee, Norris Breast Center, NCCC, Los Angeles, CA, 1990-2001

Chairman, LAC/USC Cancer Committee, 1989-1993

Member, Residency Review Committee, USC Department of Medicine, 1991-1996

Member, Educational Officers, USC Department of Medicine, 1995-1997 Member, Professional Services Committee, USC Department of Medicine, 1995-1997

Chairman, Standards & Systems Subcommittee, USC School of Medicine, 1997

Member, Practice Operations & Development, USC School of Medicine 1997-2001

Member, Education Committee, USC Department of Medicine, 1997-2001 Medical Faculty Women’s Association, USC Keck School of Medicine, 1987-2010

USC Ambassador, USC Keck School of Medicine, 1987-2017

Member, USCP Clinical Practice Committee, USC School of Medicine,1995-2001

**D. Society Memberships**:

**National**

American Cancer Society

American College of Physicians

American Society of Breast Surgeons

American Society of Clinical Oncology

American Association of Cancer Research

European Society of Medical Oncology

1. **Service:**

**Professional Organizations**

**National**

**American Cancer Society Cancer Action Network**

**National Board of Directors, 2005-2018**

**Chair, Board of Directors 2014 - 2016**

**Vice-Chair, Board of Directors 2011-2014**

Audit Committee, 2006-2008

Awards Committee, 2009

Development Committee 2010-2012

**Chair, 2011-2012**

**American Cancer Society, Inc**

National Assembly, 2001- 2010

National Board of Directors, 2006 – 2010

Health Promotions Advisory Group, 2002-2011

**Chair, 2004-2009**

Breast Cancer Advisory Group, 2003-2011.

**Chair, 2003-2008.**

Reach to Recovery Advisory Group 2010-2013.

**Chair, 2010-2013.**

Strategic Planning and Agenda Development Committee, 2009-2011.

Advocacy and Public Policy Committee, 2004-2008

Strategic Marketing and Corporate Communications Operations Committee, 2004-2007

Nationwide Business Group on Voluntarism, 2004-2009

Information Awareness Priority Workgroup, 2003

Organizational Preparedness Workgroup, 2003

Mission Delivery Steering Committee, 2003-2004

Ends Committee on Incidence and Mortality, 2006-2009

Futuring Strategic Workgroup, 2007-2008

**Chair,** Policy Review Group: Medicare and Cancer Care, 2004

Clinical Trials Advisory Workgroup, 2003-2006

Advisory Committee, Environmental Factors and Cancer, 2002-2003

**Board of Directors, National Accreditation Program for Breast Centers,** 2007-2009

**ASCO Representative, Association of Specialty Professors Council,** 2008-2011

**Executive Committee, American Society of Clinical Oncology Training Programs,** 2004- 2007

**State and Local**

**American Cancer Society**

**California Division**

Board Member, 1998-2011.

President, California 2002-2003.

**Honorary Life Board Member 2011- present.**

**Los Angeles County Regional Council**

**Council Member 1996-2001, 2003-2015**

**San Gabriel Valley Division**

Advisory Committee, 1996 to present

President 2000-2001.

E**arly Detection and Treatment Team, California Dialogue on Cancer (CDOC), Chair** 2004-2006.

**Editorships**

Editor, ACS CID on Breast Cancer, 2004-2107

1. **Research Activities:**

**Major Areas of Research Interest**

Prevention and Systemic Treatment of Breast Cancer

**G. Lectures:**

1. “Taxol - From Nature to Clinic.” Bristol Myers Squibb 5th Annual Clinical Medical Oncology Symposium. Mission Inn, Riverside, CA. Moderator Breast Cancer Panel. January 19-21, 1995.
2. New Chemotherapy in the 90’s. Smith Kline Beecham Community Cancer Symposium, Santa Monica, CA. April 20, 1995.
3. New Chemotherapy in the 90’s. Smith Kline Beecham Community Cancer Symposium, Riverside, CA. May 16, 1995.
4. New Chemotherapy in the 90’s. Long Beach Community Hospital Tumor Conference, Long Beach, CA. July 25, 1995.
5. Comprehensive Approach to Breast Cancer. Department of Veteran Affairs. Women’s Healthcare Conference, Los Angeles, CA. Sept. 21, 1995.
6. Controversies in the Adjuvant Treatment of Breast Cancer. St. Joseph’s Hospital Tumor Conference, Burbank, CA. October 5, 1995.
7. Update of the Use of Taxol in Breast and Ovarian Cancer. Oncology Nursing Society Educational Symposium. Universal City, CA. October 11, 1995.
8. Diagnosis and Treatment of Breast Cancer. “Update on Cancer, 1995”. Antelope Valley Hospital Symposium, Lancaster, CA. October 14, 1995.
9. Breast Cancer Prevention. Utah Oncology Society Symposium, Salt Lake City, UT. November 3, 1995.
10. Controversial Issues in Adjuvant Chemotherapy for Breast Cancer. Utah Oncology Society Symposium, Salt Lake City, UT. November 4, 1995.
11. Chemotherapy and Oncologic Emergencies. Daniel Freeman Hospital Educational Symposium, Los Angeles, CA. December 1, 1995.
12. Update on Testicular Cancer. USC Department of Medicine Grand Rounds, Los Angeles, CA. January 17, 1996.
13. Controversies in Adjuvant Therapy for Breast Cancer. Pomona Valley Medical Center Tumor Conference, Pomona, CA. January 18, 1996.
14. Adjuvant Therapy for Breast Cancer, An Update. USC Cancer Center Grand Rounds, Los Angeles, CA. February 13, 1996.
15. Adjuvant Therapy for Breast Cancer. Cottage Hospital Cancer Forum, Santa Barbara, CA. February 20, 1996.
16. Controversies in the Chemotherapeutic Management of Breast Cancer. USC “New Frontiers in Cancer Research” Symposium, Los Angeles, Ca. March 23, 1996.
17. New Therapeutic Approaches in the Treatment of Breast Cancer. “Focus ‘96, Beyond the Horizon”. California Society of Health-System Pharmacists Spring Symposium, Newport Beach, CA. March 29, 1996.
18. Adjuvant Therapy of Breast Cancer. Northridge Hospital Tumor Conference, Northridge, CA. April 4, 1996.
19. New Advances in the Management of Breast Cancer. Southern California Society of Health-System Pharmacists Continuing Education Symposium, Pasadena, CA. April 10, 1996.
20. Breast Cancer Screening and Prevention. Long Beach Community Hospital Tumor Conference, Long Beach, CA. April 23, 1996.
21. Appropriate Uses of Antiemetic Therapy. Balboa Naval Hospital Medicine Grand Rounds, San Diego, CA. May 6, 1996.
22. Advances in the Diagnosis and Treatment of Breast Cancer. San Diego Medical Center. Cancer Conference, San Diego, CA. September 6, 1996.
23. Reducing Side Effects and Complications of Chemotherapy. USC/Norris Breast Health Day. Los Angeles, CA. September 21, 1996.
24. What’s New in Breast Cancer? Wellness Community Silver Saturday at Descanso Gardens. La Canada, CA. October 5, 1996.
25. Update in Causes and Prevention of Breast Cancer. American Cancer Society Breast Health Forum. Bakersfield, CA. October 10, 1996.
26. Advances in Breast Cancer. Huntington Memorial Hospital Medical Grand Rounds, Pasadena, CA. October 25, 1996.
27. Breast Cancer: Clinical Management. USC St. George Society of the American Cancer Society. Los Angeles, CA. November 14, 1996.
28. Update on Cause and Prevention of Breast Cancer. The Ladies Philoptochos Society of St. John the Baptist Greek Orthodox Church. Anaheim, CA. February 1, 1997.
29. Advances in Therapy for Breast Cancer. Core curriculum lecture for Department of Surgery residency program at University of Southern California. Los Angeles, CA. February 15, 1997.
30. Controversies in Breast Cancer. Arcadia Methodist Hospital Tumor Board. Arcadia, CA. March 6, 1997.
31. Hormones and Breast Cancer. Breast Cancer Reconstruction Support Group. Arcadia, CA. March 10, 1997.
32. Breast Cancer - Advances in Screening and Therapy. Advances in Oncology Symposium. Santa Ana, CA. March 15, 1997
33. Breast Cancer Panel. Glamour/Hanes Hand in Hand Event. University of Southern California. March 18, 1997
34. Chemotherapy Update on Breast Cancer. Hospital Grand Rounds. Kaiser Permanente Hospital, Riverside, CA. March 19, 1997.
35. Breast Disease. Lakeside Medical Group Quarterly Primary Care Physician Dinner Meeting. Lancaster, CA April 23, 1997.
36. Hormone Replacement Therapy after Breast Cancer. Clinical Conference Program. Columbia West Hills Medical Center. West Hills, CA May 30, 1997.
37. New Agents in Breast Cancer. Pacific Oncology Society Educational Conference. Santa Monica, CA. June 9, 1997.
38. Breast Cancer Update from 1997 ASCO. Southern California Academy of Clinical Oncology Meeting. Los Angeles, CA. June 26, 1997.
39. Current Trends in First-Line Treatment in Metastatic Breast Cancer. Metastatic Breast Cancer and Taxane chemotherapy Dinner Symposium. Kansas City, MO. July 24, 1997.
40. Advances in Chemotherapy for Anthracycline-Resistant Metastatic Breast Cancer. Metastatic Breast Cancer and Taxane Chemotherapy Dinner Symposium. Spokane, WA. August 7, 1997.
41. Current Role of Chemotherapy in Breast Cancer Treatment. USC Postgraduate Refresher Course. Maui, Hawaii. August 11, 1997.
42. Tamoxifen: Good news or Bad news? USC Postgraduate Refresher Course. Maui, Hawaii. August 14, 1997.
43. The Breast Examination. Hands-On Clinical Skills Workshops. USC Postgraduate Refresher Course. Maui, Hawaii. August 15, 1997.
44. Cancer Screening and Women’s Health. Glendale Chapter of Medical Assistants Educational Forum. Pasadena, CA. September 4, 1997.
45. Overview of Breast Cancer and the Role of Adjuvant Therapy. Bristol Myers Squibb Representatives Educational Symposium. Los Angeles, CA September 16, 1997.
46. Recent Advances in the Treatment of Breast Cancer. Bakersfield Cancer Forum. Bakersfield, CA. September 17, 1997.
47. Tamoxifen and Other Antiestrogens. USC/Norris Sixth Annual Breast Health Day. Los Angeles, CA. September 20, 1997.
48. The Use of Hormone Therapy After Breast Cancer. Metropolitan MSA Family Practice Symposium. Beverly Hills, CA October 23, 1997.
49. Breast Cancer and Adjuvant Therapy. Kaiser Permanente Sunset Radiation Oncology Meeting. Los Angeles, CA October 28, 1997.
50. Management of Metastatic Breast Cancer. USC Postgraduate Symposium. Current Treatment and Future Directions in the Management of: Breast Cancer, Non-Hodgkin’s Lymphoma, Non-Small Cell Lung Cancer and Genitourinary Malignancies. Speaker and Program Chairperson. Pasadena, CA. November 8, 1997
51. Estrogen Replacement Therapy After Breast Cancer: Pros and Cons. The Cancer Foundation of Santa Barbara Grand Rounds. Santa Barbara, CA. December 2, 1997.
52. Breast Cancer: An Update. The San Gabriel Valley Medical Center Tumor Conference. San Gabriel, CA. January 29, 1998.
53. Breast Cancer. Kaiser Permanente Los Angeles Gynecology Grand Rounds. Los Angeles, CA February 19, 1998.
54. Breast Cancer Diagnosis and Management. 26th Annual Diagnostic and Therapeutic Skills in Internal Medicine. Mauna Kea, Hawaii. March 9, 1998.
55. Cancer Prevention: The Place of Medications, Vitamins, and Lifestyle. 26th Annual Diagnostic and Therapeutic Skills in Internal Medicine. Mauna Kea, Hawaii. March 10, 1998.
56. Genetic Testing for Cancer Susceptibility. 26th Annual Diagnostic and Therapeutic Skills in Internal Medicine. Mauna Kea, Hawaii. March 11, 1998.
57. Screening Recommendations for Cancer. 26th Annual Diagnostic and Therapeutic Skills in Internal Medicine. Mauna Kea, Hawaii. March 13, 1998.
58. Invasive Breast Cancer - Primary and Adjuvant Therapy. Memorial Hospital of Gardena Tumor Conference. Gardena, CA. March 16, 1998.
59. Micrometastatic Cancer and Its Clinical Impact, A Panel Discussion. Society of Surgical Oncology 51st Annual Meeting, San Diego, CA. March 26, 1998.
60. Updates in the Treatment of Breast Cancer. California Society of Hospital Pharmacists Focus 1998 Meeting. Lake Tahoe, NV. April 3, 1998.
61. Health, Humor, and Hormones - What Women in the 2000’s Will Be Facing. 1998 Options Unlimited Women’s Business Conference. Bakersfield, CA. April 16, 1998.
62. Estrogen Replacement Therapy After Breast Cancer: Is It Safe? St. Vincent Medical Center Oncology Conference. Los Angeles, CA April 17, 1998.
63. Can Lifestyle and Diet Prevent Breast Cancer? A Celebration of Spirit, Orange County Regional Cancer Center Symposium. Santa Ana, CA September 26, 1998.
64. The Prevention of Breast Cancer. Huntington Memorial Hospital Cancer Symposium. Pasadena, CA October 5, 1998.
65. Breast Cancer Awareness. Health Conference. Jet Propulsion Lab employees. Pasadena, CA. November 3, 1998.
66. Breast Cancer Prevention. Santa Monica Hospital Grand Rounds. Santa Monica, CA November 4, 1998.
67. Recent Advances in the Treatment of Metastatic Breast Cancer. Southern California Academy of Clinical Oncology Meeting. Los Angeles, CA November 18, 1998.
68. The Prevention of Breast Cancer. St. John’s Regional Medical Center Tumor Conference. Oxnard, CA November 24, 1998.
69. New Therapeutics in the Treatment of Metastatic Breast Cancer. Portland Oncology Symposium. Portland, Oregon November 30, 1998.
70. Reducing the Incidence of Breast Cancer in Women at High Risk. Thousand Oaks Oncology conference. Thousand Oaks, CA December 17, 1998.
71. Reducing the Incidence of Breast Cancer in Women at High Risk. Las Vegas Oncology conference. Las Vegas, NV January 13, 1999.
72. Reducing the Incidence of Breast Cancer in Women at High Risk. Phoenix Oncology conference. Phoenix, AZ January 14, 1999.
73. Reducing the Incidence of Breast Cancer in Women at High Risk. Saint Agnes Medical Center Tumor Board meeting. Fresno, CA January 20, 1999.
74. New Advances in Breast Cancer. Holy Cross Medical Center Tumor Conference. Mission Hills, CA January 29, 1999.
75. Reducing the Incidence of Breast Cancer in Women at High Risk. Oncology Nursing Society Lecture Series. Beverly Hills, CA February 10, 1999.
76. Reducing the Incidence of Breast Cancer in Women at High Risk. Cottage Hospital Grand Rounds. Santa Barbara, CA February 17, 1999.
77. Reducing the Incidence of Breast Cancer in Women at High Risk. Sutter Women’s Health Conference. Sacramento, CA February 27, 1999.
78. Reducing the Incidence of Breast Cancer in Women at High Risk. Contemporary Concerns in Women’s Health Conference. Swedish Medical Center. Seattle, Washington. April 16, 1999.
79. What’s New in Systemic Treatment of Both Early and Metastatic Breast Cancer. Cancer Care’99 Conference. Great Falls, Montana. April 22, 1999
80. Reducing the Incidence of Breast Cancer in Women at High Risk. Cancer Care ’99 Conference. Great Falls, Montana. April 22, 1999.
81. New Breast Cancer Prevention Strategies. The Fourth Annual Primary Care Provider Conference, Mercy Medical Center. Redding, California. April 24, 1999.
82. Breast Cancer Prevention. Medicine Grand Rounds, Queen of the Valley Hospital. West Covina, CA. May 3, 1999.
83. Reducing the Incidence of Breast Cancer in Women at High Risk. Community physician lecture. Fresco’s Restaurant, Glendale, CA. May 12, 1999.
84. New Trends in the Early Detection and Management of Breast Cancer. Cancer Initiative 2000 Neurooncology and Oncology Symposium. Monterey, CA. May 26, 1999.
85. Breast Cancer Prevention. Orange County Cancer Community Forum. Fountain Valley, CA. June 29, 1999.
86. Reducing the Incidence of Breast Cancer in Women at High Risk. Medical Grand Rounds. Little Company of Mary Hospital, Torrance, CA. July 14, 1999.
87. Reducing the Incidence of Breast Cancer in Women at High Risk. Community Physician Forum, Phoenix, AZ. July 15, 1999.
88. What’s New in the Treatment of Metastatic Breast Cancer. Pasadena Oncology Update. Pasadena, CA. July 22, 1999.
89. Reducing the Incidence of Breast Cancer in Women at High Risk. Medical Grand Rounds. Irvine Medical Center, Irvine, CA. July 26, 1999.
90. Breast Cancer Update. Los Angeles Oncology Forum, Beverly Hills, CA. September 16, 1999.
91. New Therapeutics in Metastatic Breast Cancer. Oncology Grand Rounds, University of California, Irvine. Irvine, CA September 24, 1999.
92. Reducing the Incidence of Breast Cancer in Women at High Risk. Las Vegas Oncology Update. Las Vegas, NV October 2, 1999.
93. Reducing the Incidence of Breast Cancer in Women at High Risk. Medical Grand Rounds. Placentia Medical Center, Placentia, CA. October 4, 1999.
94. Reducing the Incidence of Breast Cancer in Women at High Risk. Central Valley Oncology Update, Chico, CA. October 6, 1999.
95. Updates in the Prevention and Treatment of Breast Cancer. Redding Oncology Forum, Redding, CA. October 6, 1999.
96. Reducing the Incidence of Breast Cancer in Women at High Risk. Medical Grand Rounds. San Luis Obispo Community Medical Center. San Luis Obispo, CA. October 8, 1999.
97. How Do We Prevent and Diagnose Breast Cancer? American Cancer Society Education Forum at Jet Propulsion Lab. Pasadena, CA. October 14, 1999.
98. Current Therapeutics in Early Breast Cancer. Oncology Lecture Series. Los Angeles County Medical Center. October 15, 1999.
99. Update on the Prevention of Breast Cancer. Medical Grand Rounds. Loma Linda University Medical Center, Loma Linda, CA. October 20, 1999.

100. Update on the Prevention of Breast Cancer. American Cancer Society Community Forum on Breast Cancer. Honolulu, HI October 30, 1999.

1. Updates in the Prevention and Treatment of Invasive and Non-invasive Breast Cancer. Hawaii Oncology Symposium, Honolulu, HI October 30, 1999.
2. Optimizing the Use of Chemotherapy for Metastatic Breast Cancer. Oncology Grand Rounds. Panorama City Kaiser Permanente Hospital. Panorama City, CA. November 3, 1999.
3. Adjuvant Systemic Therapy for Early Breast Cancer. Oncology Nursing Society Annual Meeting. Salt Lake City, UT November 12, 1999.
4. Medical Prophylaxis of Breast Cancer. New Concepts in Medicine. 35th Annual Staff Seminar. California Hospital Medical Center, Los Angeles, CA. November 12, 1999.
5. Reducing the Incidence of Breast Cancer in Women at High Risk. Southern California Breast Cancer Oncology Update. Huntington Beach, CA. November 13, 1999.
6. Update on Breast Cancer Prevention. Gynecology Cancer Update. Manhattan Beach, CA. November 14, 1999.
7. Reducing the Incidence of Breast Cancer in Women at High Risk. Medical Grand Rounds, Beaver Medical Center. Highland, CA. November 19, 1999.
8. Reducing the Incidence of Breast Cancer in Women at High Risk. Medical   
   Grand Rounds. Torrance Memorial Hospital, Torrance, CA. December 1, 1999.
9. Chemoprevention of Breast Cancer: The Role of Tamoxifen. 52nd Annual Midwinter Radiation Oncology Conference, Los Angeles Radiological Society. Hollywood, CA. January 22, 2000.
10. Reducing the Incidence of Breast Cancer in Women at High Risk. Community Gynecology Conference. Phoenix, AZ. January 19, 2000.
11. Metastatic Breast Cancer. LAC/USC Internal Medicine Core Curriculum Lecture. Los Angeles, CA. January 25, 2000.
12. Breast Cancer Prevention. Regional Gynecology Meeting. Phoenix, AZ. May 1, 2000.
13. Breast Cancer Prevention. Regional Gynecology Meeting. Los Angeles, CA. May 11, 2000.
14. Breast Cancer Controversies. Tumor Conference. Community Hospital of the Monterey Peninsula. June15, 2000.
15. New Therapeutics for Metastatic Breast Cancer –The Role of HER-2-neu. Oncology Grand Rounds. Kaiser Permanente Sunset. Los Angeles, CA. June 27, 2000.
16. Controversies in the Treatment of Early Breast Cancer. Community Oncology Forum. Phoenix, AZ. July 24, 2000.
17. The Systemic Treatment of Early Breast Cancer. Oncology Grand Rounds. Maricopa County Hospital. Phoenix, AZ. July 25, 2000.
18. Prevention of Breast Cancer. Oncology Nursing Society Annual Meeting. Tucson, AZ. July 25, 2000.
19. The Facts About Breast Cancer: It’s Not Your Fault. American Cancer Society Surviving and Thriving After Cancer Conference. Riverside, CA. July 16, 2000.
20. Women and Cancer: Beating the Odds. Los Angeles Times Festival of Health. Los Angeles, CA. September 16, 2000.
21. Breast Cancer Awareness. Soroptimist International Shasta Cascade and American Cancer Society. Redding, CA. October 5, 2000.
22. Breast Cancer Awareness and Prevention. American Cancer Society Community Forum. Yuba City, CA. October 10, 2000.
23. Breast Cancer Update. Tumor Conference. Global Care Medical Center. Montclair, CA. October 12, 2000.
24. Breast Cancer Update. Grand Rounds. Memorial Hospital of Gardena. Gardena, CA. October 16, 2000.
25. Hormone Replacement Therapy and DCIS. American College of Surgeons Annual Meeting. Chicago, IL. October 24, 2000.
26. Breast Cancer Cause and Prevention. Michianda Breast Cancer Conference. South Bend, IN. October 27, 2000.
27. Demystifying Tamoxifen. Norris Cancer Hospital Breast Cancer Forum. Los Angeles, CA. November 9, 2000.
28. Update on San Antonio Breast Cancer Meeting. Southern California Academy Clinical Oncology. Los Angeles, CA. January 10, 2001
29. Breast Cancer Awareness and Prevention. American Cancer Society Reach to Recovery Meeting. Riverside, CA. February 10, 2001.
30. Hormone Therapy in Metastatic Breast Cancer. Orange County Oncology Forum. Costa Mesa, CA. February 21, 2001.
31. Breast Cancer Update. Grand Rounds. Sherman Oaks Hospital. Sherman Oaks, CA. March 1, 2001.
32. The Interdisciplinary Breast Conference: Case Presentations and Patient Management Encompassing the Entire Spectrum of Medicine. 11th Annual National Interdisciplinary Breast Center Conference. The National Consortium of Breast Centers, Las Vegas, NV. March 19, 2001.
33. Role of New Agents in Metastatic Breast Cancer. California Society of Hospital Pharmacists – Spring Symposium. Pasadena, CA. March 10, 2001.
34. Update on Breast Cancer. American Cancer Society – Reach to Recovery update and training. Panorama City, CA. March 31, 2001.
35. Update on Breast Cancer. American Cancer Society – Reach to Recovery update and training. Torrance, CA, April 28, 2001.
36. Breast Cancer: Prevention, Diagnosis, and Treatment. American Cancer Society – Reach to Recovery Volunteer Annual Meeting. San Francisco, CA, May 17, 2001.
37. ASCO Review 2001 – Breast Cancer. Duke Oncology Consortium Annual Meeting. Greensboro, NC, June 9, 2001.
38. Hope, Health, and Healing. Advances and New Directions in Breast Cancer. American Cancer Society Community Symposium. Hoag Memorial Hospital, Newport Beach, CA, September 15, 2001.
39. What’s New in Breast Cancer? USC/Norris Breast Cancer Support Group Meeting. USC/Norris Cancer Hospital, Los Angeles, CA. September 20, 2001.
40. Hormone Therapy for Metastatic Breast Cancer – An Update. Cottage Hospital Tumor Conference. Santa Barbara, CA. October 2, 2001.
41. Advances and New Directions in Breast Cancer – Community Oncologist Update. Santa Monica, CA. November 10, 2001.
42. Bone metastases and Bisphosphonates. Community Oncology Update. Los Angeles, CA. November 11, 2001.
43. Breast Cancer Overview. LAC/USC Internal Medicine Core Curriculum Lecture. Los Angeles, CA. January 18, 2002.
44. Cancer Screening and Prevention. American Cancer Society Gold Coast Leadership Conference. Santa Barbara, CA. February 9, 2002.
45. Systemic Therapy for Metastatic Breast Cancer. Oncology Community Forum. Boston, MA. February 12, 2002.
46. Common Cancers in Women – Role of Diet, Nutrition, and Physical Activity. Community Health Symposium. Skirball Center, Brentwood, CA. February 23, 2002.
47. Hormones and Breast Cancer 2002. Astra-Zeneca Advisory Board Meeting. San Francisco, CA. April 6, 2002.
48. Hormones and Breast Cancer 2002. Oncology Community Forum. Las Vegas, NV. April 20, 2002.
49. Hormone Therapy for Early and Metastatic Breast Cancer. West Coast Oncology Forum. Santa Barbara, CA. April 27, 2002.
50. Breast Cancer Dilemmas. LA Surgical Society Meeting. Los Angeles, CA. October 3, 2002.
51. Hormone Therapy in Early and Advanced Breast Cancer. Kaiser Permanente Riverside Tumor Conference. Riverside, CA. October 3, 2002.
52. Support Groups and Cancer. 2002 Los Angeles Times Festival of Health and Fitness. Panel Discussion: Christy Russell, Rob Lowe, Marcia Brandwynne. Los Angeles, CA October 6, 2002.
53. Update on Treatment of Breast Cancer 2002. LAC/USC Medicine Lecture Series. Los Angeles, CA. October 24, 2002.
54. Hormone Therapy for Breast Cancer. Kaiser Permanente Baldwin Park Tumor Conference. Baldwin Park, CA. November 6, 2002.
55. Challenging Cases in Breast Cancer. Network for Oncology Communication and Research. The Ritz Carlton – Marina del Rey, Marina del Rey, CA. November 9, 2002.
56. San Antonio Breast Cancer Symposium Update. Network for Oncology Communication and Research Symposium. The Ritz Carlton – New Orleans, New Orleans, LA. February 1, 2003.
57. Highlights of the 2002 San Antonio Breast Cancer Meeting. Cottage Hospital Tumor Conference. Santa Barbara, CA. February 4, 2003.
58. San Antonio Breast Cancer Symposium Update. Network for Oncology Communication and Research Symposium. The Essex House – New York City, NY. February 15, 2003.
59. Current Controversies with Hormone Treatment and Breast Cancer. 13th Annual National Interdisciplinary Breast Center Conference. National Consortium of Breast Centers, Inc. Las Vegas, NV. February 23, 2003.
60. Chemotherapy for Early and Advanced Breast Cancer. . 13th Annual National Interdisciplinary Breast Center Conference. National Consortium of Breast Centers, Inc. Las Vegas, NV. February 24, 2003.
61. Hormone Issues and the Breast. 12th Annual Oncology Symposium for Healthcare Professionals. Torrance Memorial Cancer Center. Torrance, CA. March 7, 2003.
62. Advances in Metastatic Breast Cancer. Tumor conference, Sequoia Regional Cancer Center. Visalia, CA March 19, 2003.
63. Advances in Metastatic Breast Cancer. California Cancer Center Tumor Conference. Fresno, CA. March 19, 2003.
64. Cases in Early and Advanced Breast Cancer – NOCR Conference. Torrey Pines, CA. May 10, 2003.
65. Hormone Therapy in Early and Advanced Breast Cancer. Astra-Zeneca Advisory Group Meeting. Seattle, WA. May 23, 2003.
66. Post-ASCO Breast Cancer Update. Phoenix Cancer Center Tumor Conference. Phoenix, AZ. June 10, 2003.
67. Metastatic Breast Cancer Update. San Luis Obispo and Santa Maria Oncology Tumor Conference. Pismo Beach, CA. July 16, 2003.
68. Challenging Cases in Breast Cancer – NOCR Conference. Four Seasons Hotel, Las Vegas, NV. June 21, 2003.
69. ASCO Highlights – NOCR Conference. Supportive Care and Breast Cancer. Hyatt Regency La Jolla. La Jolla, CA. July 26, 2003.
70. NOCR Breast Cancer Key Thought Leaders Meeting. Aromatase Inhibitors and Breast Cancer. Beaver Creek, CO. August 16, 2003.
71. Update in the Management of Advanced Breast Cancer. Presbyterian Intercommunity Hospital Tumor Board. Whittier, CA. August 19, 2003.
72. Challenging Cases in Breast Cancer – NOCR Conference. Marriott’s Camelback Inn, Scottsdale, AZ. September 6, 2003.
73. National Dialogue on Cancer Primary Prevention and Early Detection Summit. Cancer Early Detection Tests and Efforts Unique to Women. Atlanta Marriott Marquis. Atlanta, GA. September 18, 2003.
74. Update in the Management of Early Breast Cancer. Kaiser Permanente Sunset Tumor Conference. Los Angeles, CA. September 23, 2003
75. Breast Cancer Risk and Prevention. Well Woman Annual Conference. Good Samaritan Medical Center. Los Angeles, CA. October 11, 2003
76. Update on the Role of Herceptin for HER-2 Amplified Breast Cancer. Community Oncology Conference. Beverly Hills, CA. October 14, 2003.
77. Update on Hormone Therapy for Early and Advanced Breast Cancer. Community Oncology Conference. La Jolla, CA. October 15, 2003.
78. Update on the Role of Herceptin for HER-2 Amplified Breast Cancer. Community Oncology Conference. Paso Robles, CA. October 22, 2003.
79. Cancer in California. Reasons for a State Cancer Plan. California Cancer Registrars Annual Meeting. Ontario, CA. October 24, 2003.
80. Role of Hormone Therapy in Early Breast Cancer. Novartis Western Region Consultants Meeting. Las Vegas, NV. October 25, 2003.
81. Early and Advanced Breast Cancer: A Case Study Approach. St. Joseph’s Hospital Tumor Conference. Burbank, CA. October 30, 2003.
82. The Effects of Bone Loss in Early Breast Cancer. NOCR Thought Leaders on Bone and Cancer. Palm Beach, Florida. November 8, 2003.
83. Hormone Therapy in Early Breast Cancer. Oncology Nursing Society Meeting. Las Vegas, NV. November 17, 2003.
84. Role of Ovarian Ablation in Premenopausal Women with Early Breast Cancer. NOCR Challenging Cases in Breast Cancer. San Antonio, CA. December 2, 2003.
85. Updates in Neoadjuvant and Adjuvant Therapy of Breast Cancer. NOCR San Antonio Breast Cancer Symposium Highlights. Las Vegas, NV January 31, 2004.
86. Hormonal Therapy of Breast Cancer: Preparing Femara for an Expanded Role. Novartis Advisory Board. Las Vegas, NV, January 30, 2004.
87. Diagnosis, Prognosis, and Prevention of Breast Cancer. NOCR San Antonio Breast Cancer Symposium Highlights. New York, NY. January 24, 2004.
88. Managing HER-2 Positive Metastatic Breast Cancer: The Role of Herceptin. Palm Springs Oncology Tumor Conference. Palm Desert, CA. January 28, 2004.
89. Medical Oncology Management of Breast Cancer: The Interdisciplinary Care Panel: A Real-Time Management Experience. 14th Annual National Interdisciplinary Breast Center Conference. Las Vegas, NV. February 23, 2004.
90. Chemotherapy: Side Effects and Helping the Patient Cope. 14th Annual National Interdisciplinary Breast Center Conference. Las Vegas, NV. February 24, 2004.
91. The Management of HER-2 Positive Metastatic Breast Cancer: The Role of Herceptin. Las Vegas Tumor Symposium. Las Vegas, NV. March 11, 2004.
92. The Management of HER-2 Positive Metastatic Breast Cancer: The Role of Herceptin. East San Gabriel Valley Tumor Conference. Covina, CA. March 17, 2004.
93. Current Advances with Aromatase Inhibitors in Breast Cancer. California Hospital Medical Center Cancer Conference. Los Angeles, CA. April 7, 2004.
94. New Approaches to Metastatic Breast Cancer. California Cancer Consortium Conference. Santa Monica, CA. April 16, 2004.
95. Recent Developments in the Adjuvant Therapy of Breast Cancer. Monthly Round Table Conference. Glendale Adventist Hospital. Glendale, CA May 12, 2004.
96. Evolving Strategies in the Management of Breast and Thoracic Cancers: A Focus on Challenging Cases. Network for Oncology Communication and Research Regional Advisory Board. Beverly Hills, CA. May 14, 2004.
97. Extended Adjuvant Hormonal Therapy; Bisphosphonate therapy for Advanced Breast Cancer; First Line Metastatic Chemotherapy. Challenging Cases in Breast Cancer: NOCR Conference. Beverly Hills, CA May 15, 2004.
98. Zoledronic Acid and Bone Metastases. Novartis Regional Consultants Roundtable. NOCR Conference. New York, NY. May 22, 2004
99. Bisphosphonate Therapy and Bone Metastases. Alta Bates Tumor Conference. Berkeley, CA. May 26, 2004.
100. Clinical Approaches to Breast Cancer-Related Bone Loss. National Oncology Alliance – Zometa Speaker Training Program. San Francisco, CA. June 19, 2004.
101. Understanding Targeted Biologic Therapies in the Treatment of HER2-Positive Metastatic Breast Cancer. HER-family Education Network. Morristown, NJ. August 6, 2004.
102. ASCO Highlights: Breast Cancer Update. NOCR Conference. New York, NY. August 7, 2004.
103. ASCO Highlights: Breast Cancer Update. NOCR Conference. Miami Beach, FL. August 17, 2004.
104. Understanding Targeted Biologic Therapies in the Treatment of HER2-Positive Metastatic Breast Cancer. HER-family Education Network. Shell Beach, CA September 7, 2004.
105. Clinical Applications of Aromatase Inhibitor Therapy for Hormone Receptor-Positive Breast Cancer: A Case Study Approach. Health Science Center for Continuing Medical Education. Pasadena, CA. September 8, 2004.
106. Breast Cancer: Chemotherapy Update. Post-ASCO Emerging Trends in Oncology. Physician’s Education Resource Conference. Beverly Hills, CA. September 11, 2004.
107. Hormonal Therapy for Advanced Breast Cancer. NOCR Women’s Oncology Forum. Phoenix, AZ. October 2, 2004.
108. Bisphosphonate Therapy for Advanced Breast Cancer. NOCR Challenging Cases in Breast Cancer. Boston, MA. October 23, 2004.
109. Emerging Novel Agents in the Treatment of Metastatic Breast Cancer. Sixth Annual Lynn Sage Cancer Symposium. Chicago, IL. October 30, 2004.
110. Hormonal Therapy and Bisphosphonate Therapy for Metastatic Breast Cancer. NOCR Challenging Cases in Breast Cancer. Fort Lauderdale, FL. November 20, 2004.
111. Optimizing Therapeutic Outcomes in Metastatic Breast Cancer: 2004 Update. San Antonio Breast Cancer Symposium – CME Certified Symposium. San Antonio, TX. December 8, 2004.
112. Updates of Adjuvant and Neoadjuvant Breast Cancer Therapy. NOCR San Antonio Breast Cancer Highlights – 2005. Chicago, IL January 29, 2005.
113. Adjuvant Therapy for Breast Cancer: Overview and Update. The International Forum on Breast Cancer. Beijing, China. February 23, 2005
114. Treatment of Early Stage Breast Cancer: Neoadjuvant Therapy. The International Forum on Breast Cancer. Beijing, China. February 23, 2005.
115. Adjuvant Therapy for Breast Cancer: Overview and Update: Hormone Therapy. The International Forum on Breast Cancer. Beijing, China. February 24, 2005.
116. The Role of Abraxane Therapy in Metastatic Breast Cancer: A Clinical Forum. Pasadena, CA. March 15, 2005.
117. Treatment of ER (+) Advanced Breast Cancer. NOCR Challenging Cases in Geriatric Oncology. San Francisco, CA. April 2, 2005.
118. Systemic Chemotherapy in Breast Cancer: Update From SABCS. Oncology Best Practices 2005 (CME program by Baylor University). West Hollywood, CA. April 5, 2005.
119. Update in Hormone Therapy of Breast Cancer. Tumor Grand Rounds. Presbyterian Intercommunity Hospital of Whittier. Whittier, CA. April 5, 2005.
120. Breast Cancer: Systemic Therapy Update. Hoag Cancer Center Grand Rounds. Hoag Memorial Hospital. Newport Beach, CA. April 7, 2005.
121. Systemic Chemotherapy in Breast Cancer: Update From SABCS. Oncology Best Practices 2005 (CME program by Baylor University). Las Vegas, NV. April 7, 2005.
122. Metastatic Breast Cancer. Current Status and New Developments in the Diagnosis and Treatment of Breast Cancer Symposium. City of Hope Medical Center, Duarte, CA. April 30, 2005.
123. Skeletal Complications Across the Cancer Continuum CME Lecture. Salt Lake City, UT. May 11, 2005.
124. Skeletal Complications Across the Cancer Continuum CME Lecture. Las Vegas, NV. May 18, 2005.
125. Adjuvant Hormonal Therapy for Breast Cancer. NOCR Challenging Cases in Breast Cancer. Phoenix, AZ. June 4, 2005.
126. Systemic Chemotherapy and Hormonal Therapy for Breast Cancer: Update from ASCO. Oncology Best Practices CME Symposium from Physicians’ Education Resource. Portland, OR. June 15, 2005.
127. Systemic Chemotherapy and Hormonal Therapy for Breast Cancer: Update from ASCO. Oncology Best Practices CME Symposium from Physicians’ Education Resource. San Diego, CA. June 22, 2005.
128. Update on Adjuvant Hormonal Therapy in Breast Cancer. NOCR Oncology Highlights CME Symposium. Hollywood, FL. June 25, 2005.
129. Skeletal Complications Across the Cancer Continuum CME lecture. New Brunswick, NJ. June 29, 2005.
130. Metastatic Breast Cancer – The Role of Abraxane. Abraxis Oncology Expert Roundtable. Santa Ana, CA. July 6, 2005.
131. Update on Adjuvant Hormonal Therapy in Breast Cancer. NOCR Oncology Highlights CME Symposium. San Francisco, CA. July 9, 2005.
132. Current Management of Breast Cancer. Irvine Regional Hospital and Medical Center CME Educational Conference. Irvine, CA. July 13, 2005.
133. Metastatic Breast Cancer – The Role of Abraxane. Abraxis Oncology Expert Roundtable CME Conference. Sacramento, CA. July 13, 2005.
134. Adjuvant Chemotherapy – When to be Aggressive and When to be Cautious. Reality Oncology: Your Most Challenging Cases in Breast Cancer NOCR CME meeting. Portland, OR. July 16, 2005.
135. Metastatic Breast Cancer – Controversies in Chemotherapy and Biologic Agents. Reality Oncology: Your Most Challenging Cases in Breast Cancer NOCR CME meeting. Portland, OR. July 16, 2005.
136. ASCO Highlights. Updates on Hormone Therapy for Breast Cancer. NOCR CME meeting. New York, NY. July 23, 2005.
137. Update on Hormone Therapy for Breast Cancer. Cancer Care Oncology Lecture. Torrance, CA. July 27, 2005.
138. Update on HER-2 Amplified Breast Cancer. Community Oncology Lecture. Pasadena, CA. August 3, 2005.
139. Challenging Cases in Breast Cancer. NOCR Emerging Data Conference. Las Vegas, NV. August 13, 2005.
140. Adjuvant Chemotherapy – When to be Aggressive and When to be Cautious. Reality Oncology: Your Most Challenging Cases in Breast Cancer NOCR CME meeting. Memphis, TN. August 20, 2005.
141. Skeletal Complications Across the Cancer Continuum CME Lecture. Anaheim, CA. August 30, 2005.
142. Skeletal Complications Across the Cancer Continuum CME lecture. Seattle, WA. August 31, 2005.
143. Advanced Breast Cancer – The Role of Chemotherapy in ER/PR/HER-2 Negative Breast Cancer. NOCR Challenging Cases in Geriatric Oncology. New York, NY. September 10, 2005.
144. The Role of Hormone Therapy in Postmenopausal Women. NOCR Challenging Cases in Breast Cancer. Las Vegas, NV. September 17, 2005.
145. Adjuvant Therapy for Breast Cancer. Doctor’s Hospital Medical Center Oncology Symposium. Monterey, CA. September 18, 2005
146. Management of HER2-Positive Metastatic Breast Cancer: The Role of Herceptin. Community Oncology Forum. Fresno, CA. September 21, 2005.
147. Great Debates in Breast Cancer. An American School of Oncology CME meeting. Lake Tahoe, NV. October 28-29, 2005.
148. Abraxis Oncology Expert Roundtable. Ventura Oncology Forum. Ventura, CA. November 10, 2005.
149. Therapy of Metastatic Breast Cancer. Challenging Cases in Oncology. An NMCR CME lecture series. Hollywood, FL. November 12, 2005.
150. Update on Metastatic Breast Cancer. Tumor Grand Rounds. Good Samaritan Hospital. Los Angeles, CA. December 12, 2005.
151. Update on Breast Cancer. Glendale Adventist Medical Center Grand Rounds. Glendale, CA. December 14, 2005.
152. Management of HER-2 Positive Metastatic Breast Cancer: The Role of Herceptin. Santa Monica Oncology Physicians groups. Santa Monica, CA. December 14, 2005.
153. Management of HER-2 Positive Metastatic Breast Cancer: The Role of Herceptin. Harbor UCLA Medical Center Tumor Symposium. Torrance, CA. December 15, 2005.
154. The Evolving Role of HER2-Targeted Therapies in Breast Cancer. Cancer Center of Santa Barbara Grand Rounds. Santa Barbara, CA. January 3, 2006.
155. Management Strategies for Hormone-Receptor Positive Breast Cancer in the Adjuvant Setting. A CME program sponsored by the Annenberg Center for Health Sciences. Omaha, NE. January 11, 2006.
156. Endocrine Therapy of Breast Cancer. San Antonio Breast Cancer Symposium Highlights Meeting. The American School of Oncology CME Meeting. Philadelphia, PA. January 21, 2006.
157. Management of Pre and Post-Menopausal, Hormone Receptor Positive Breast Cancer. Cancer 2006 preferred Treatment and Management Options. Hoag Cancer Center CME Meeting. Huntington Beach, CA. January 27, 2006.
158. Endocrine Therapy of Breast Cancer. San Antonio Breast Cancer Symposium Highlights Meeting. The American School of Oncology CME Meeting. Ft. Lauderdale, FL. January 28, 2006.
159. Endocrine Therapy of Breast Cancer. San Antonio Breast Cancer Symposium Highlights Meeting. The American School of Oncology CME Meeting. San Francisco, CA. February 11, 2006.
160. Primary Prophylaxis and Treatment of Chemotherapy Induced Neutropenia. An International Oncology Network San Antonio Breast Review. Las Vegas, Nevada. February 12, 2006.
161. Adjuvant Endocrine Therapies: A 2006 Perspective. Oncology Best Practices 2006. Physicians Education Resource CME Conference. Chicago, IL. February 15, 2006.
162. Hormonal Therapy of Breast Cancer 2006: Making Sense of it All. Clinical Hematology and Oncology. Scripps Cancer Center’s 26th Annual Conference. San Diego, CA. February 20, 2006.
163. Targeted Agents and Emerging Chemotherapy Drugs for Metastatic Breast Cancer. Oncology Best Practices 2006. Physicians Education Resource CME Conference. Portland, OR. February 22, 2006.
164. Treatment of Triple-negative Metastatic Breast Cancer. NOCR Challenging Cases in Breast Cancer Symposium. Chicago, IL. February 25, 2006.
165. Early Stage Breast Cancer Treatment Decision Making. California Hematology Oncology Medical Group Educational Roundtable. Brentwood, CA. March 9, 2006.
166. Adjuvant Endocrine Therapies: A 2006 Perspective. Oncology Best Practices 2006. Physicians Education Resource CME Conference. San Francisco, CA March 15, 2006.
167. Systemic Treatment of Metastatic Breast Cancer. NOCR Challenging Cases in Oncology Symposium. San Diego, CA. April 1, 2006.
168. Integrating Novel Therapeutic Approaches into the Treatment of Breast Cancer. Educational Concepts CME Conference. Seattle, WA. April 19, 2006.
169. Adjuvant Therapy for Invasive Breast Cancer. Have We Made Advances in the Prevention, Diagnosis, and Treatment of Breast and Ovarian Cancers? City of Hope National Medical Center CME Symposium. Duarte, CA. April 22, 2006.
170. Adjuvant Therapy for Colorectal Cancer in the USA. Chinese-American Surgical Oncology Week 2006 Symposium. School of Oncology Peking University. Beijing, China. May 9, 2006.
171. Adjuvant Therapy for Breast Cancer in the USA. Chinese-American Surgical Oncology Week 2006 Symposium. School of Oncology Peking University. Beijing, China. May 9, 2006.
172. Updates in Targeted Therapies for HER2-Positive Breast Cancer. Hollywood Presbyterian Medical Center Medical Education Conference. Los Angeles, CA. May 24, 2006.
173. Advances in Biologic Therapies and Novel Agents for Breast Cancer. Emerging Trends in Oncology: Updates from 2006 AACR and ASCO meetings. Physicians Educational Resource Group CME Meeting. San Francisco, CA. June 10, 2006.
174. Advanced Breast Cancer – The Role of Chemotherapy in ER/PR/HER-2 Negative Breast Cancer. NOCR Challenging Cases in Breast Cancer. San Francisco, CA. June 17, 2006.
175. Hormone Therapy for Postmenopausal Women with Early-Stage Hormone Receptor-Positive Breast Cancer. Oncology Nursing Society Educational CME Forum. Las Vegas, NV. June 21, 2006.
176. Update on Chemotherapy and Novel Targeted Agents in Metastatic Breast Cancer. Oncology Best Practices CME Meeting. Phoenix, AZ. July 26, 2006.
177. Breast Cancer ASCO Highlights 2006. American School of Oncology NOCR Highlights. Chicago, IL. July 29, 2006.
178. Breast Cancer ASCO Highlights 2006. American School of Oncology NOCR Highlights. Detroit, MI. August 5, 2006.
179. Breast Cancer ASCO Highlights 2006. American School of Oncology NOCR Highlights. New York, New York. August 12, 2006.
180. HER2-Targeted Therapy in the Treatment of Metastatic Breast Cancer. Genentech BioOncology Community Lecture. Modesto, CA. August 16, 2006.
181. HER2-Targeted Therapy in the Treatment of Metastatic Breast Cancer. Genentech BioOncology Community Lecture. Stockton, CA, August 17, 2006.
182. HER2-Targeted Therapy in the Treatment of Metastatic Breast Cancer. Genentech BioOncology Community Lecture. San Jose, CA. August 17, 2006.
183. HER2-Targeted Therapy in the Treatment of Metastatic Breast Cancer. Genentech BioOncology Community Lecture. Soquel, CA. August 18, 2006.
184. Angiogenesis and VEGF Inhibitors in Breast Cancer. Panama Oncology Society Symposium. Panama City, Panama. September 2, 2006.
185. Endocrine Treatment in Breast Cancer; New Perspectives. Cyprus Oncology Associate Symposium. Nicosia, Cyprus. September 7, 2006.
186. Update on Chemotherapy and Novel Targeted Agents in Metastatic Breast Cancer. Oncology Best Practices CME Meeting. Anaheim, CA. September 28, 2006.
187. Managing Special Populations with Breast Cancer: Pregnant patients, Geriatric Patients, Patients with Co-Morbidities. Reality Oncology – Advances in Solid Tumors. Rocky Mountain Oncology Society Fall Membership Meeting. Denver, CO. September 30, 2006.
188. Managing the Primary Tumor in Patients Presenting with Stage IV Breast Cancer. Reality Oncology – Advances in Solid Tumors. Rocky Mountain Oncology Society Fall Membership Meeting. Denver, CO. September 30, 2006.
189. HER2-Targeted Therapy in the Treatment of Breast Cancer. Genentech Integrated Education Program. San Diego, CA. October 4, 2006.
190. New and Emerging Therapeutic Options in Breast Cancer Therapy. Interactive Network for Continuing Education Symposium. Chicago, IL. October 7, 2006.
191. Managing Special Populations with Breast Cancer: Pregnant Patients, Geriatric Patients, and Patients with Multiple Comorbidities. Georgia Society of Clinical Oncology Meeting. Atlanta, GA. November 5, 2006.
192. BIG 1-98 and Distant DFS – A Surrogate Marker for Overall Survival. Nordic Oncology Society. San Antonio Breast Cancer Symposium meeting. San Antonio, TX. December 16, 2006.
193. Managing HER2-Positive Breast Cancer from Early to Metastatic Disease: Advances and Future Directions. Tumor Board. Glendale Adventist Medical Center. Glendale, CA. January 10, 2007.
194. San Antonio Breast Cancer Symposium Highlights. Update on Breast Cancer Prevention. American School of Oncology CME Symposium. New York, NY. January 19, 2007.
195. Update on Hormonal Therapy of Breast Cancer. 2007 Hematology/Oncology Kaiser Permanente Symposium. Los Angeles, CA. January 26, 2007.
196. San Antonio Breast Cancer Symposium Highlights. Update on Neoadjuvant Chemotherapy for Breast Cancer. American School of Oncology CME Symposium. San Francisco, CA. January 27, 2007.
197. Overview of Abraxane in Breast Cancer. Orange County Community Oncology Forum. Santa Ana, CA. January 30, 2007.
198. San Antonio Breast Cancer Symposium Highlights. Update on Breast Cancer Prevention. American School of Oncology CME Symposium. New York, NY. February 3, 2007.
199. San Antonio Breast Cancer Symposium Highlights. Update on Breast Cancer Prevention and Endocrine Therapy. American School of Oncology CME Symposium. Chicago, IL. February 10, 2007.
200. Controversies Surrounding the Optimal Use of Chemotherapy in Breast Cancer. John C. Lincoln Health Network Hospital Tumor Conference. Phoenix, AZ. February 14, 2007.
201. Longmire Lectureship: Invasive Lobular Cancer: A Different Disease. Scripps Cancer Center’s 27th Annual Conference: Clinical Hematology & Oncology 2007. La Jolla, CA. February 20, 2007.
202. Aromatase Inhibitor Therapy for Postmenopausal Patients with Early Breast Cancer. Advances in Early Breast Cancer: Effective Treatment and Management of Postmenopausal Patients CME Symposium. 24th Annual Miami Breast Cancer Conference. Miami, FL. February 22, 2007.
203. Hormonal Therapies for Breast Cancer in the Neoadjuvant and Adjuvant Settings. Review and Interpretations of the 2006 SABCS Indiana School of Medicine CME Meeting. Huntington Beach, CA. February 24, 2007.
204. Breast Cancer Biology and Chemoprevention. Review and Interpretations of the 2006 SABCS Indiana School of Medicine CME Meeting. Huntington Beach, CA. February 24, 2007.
205. Update on HER2-Targeted Therapies and Other Novel Biologic Agents. Oncology Best Practices 2007 Physicians’ Education Resource CME Meeting.
206. Pasadena, CA. March 6, 2007.
207. Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer. Sacramento Community Oncology Forum. Sacramento, CA. March 7, 2007.
208. Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer. San Gabriel Valley Community Oncology Forum. Pasadena, CA. March 8, 2007.
209. Addressing the Risk of Early and Late Recurrence in Breast Cancer. Letrozole International Leaders Review Meeting. Zurich, Switzerland. March 13, 2007.
210. Systemic Treatment of Metastatic Breast Cancer. NMCR Challenging Cases in Breast Cancer Meeting. Chicago, IL. April 14, 2007.
211. Chemotherapy-related bone loss. Management of Chemotherapy-Related Complications: A Case-Based Approach to the Management of Mucositis, Hematologic Sequelae, and Chemotherapy Related Bone Loss. Imedex CME community oncology forum. Santa Monica, CA. April 17, 2007.
212. Examining New Adjuvant Therapy in Early Breast Cancer. Medical Education Resources CME Community Oncology Forum. Redondo Beach, CA. April 18, 2007.
213. An Update in the Treatment of HER-2-positive Metastatic Breast Cancer. Advanced Communicate and Education community oncology forum. Pasadena, CA. May 9, 2007.
214. Systemic Treatment of Metastatic Breast Cancer. NMCR Challenging Cases in Breast Cancer Meeting. Miami, Fl. May 12, 2007.
215. Aromatase Inhibitors and Bone Loss: Putting Risks in Perspective. Aromatase Inhibitors and Bisphosphonates: Improving Long-Term Breast Cancer and Bone Health Outcomes. A CME Certified Symposium. Chicago, IL. June 1, 2007.
216. Program Director Time and Resources for Success. American Society of Clinical Oncology Training Program Director’s Special Session. ASCO 2007 Annual Meeting. Chicago, IL June 3, 2007.
217. An Update in the Treatment of HER-2-positive Metastatic Breast Cancer. Advanced Communicate and Education community oncology forum. Costa Mesa, CA. June 7, 2007.
218. Oncology for the Breast Imager. 32nd Annual Spring Conference on Ultrasound and Breast Imaging. Los Angeles Radiologic Society CME meeting. Los Angeles, CA. June 10, 2007.
219. Adjuvant Chemotherapy for HER-2 (+) Breast Cancer. Challenging Cases in Geriatric Oncology NMCR Meeting. Las Vegas, NV. June 30, 2007.
220. An Update in the Treatment of HER2-positive Metastatic Breast Cancer. An Advanced Communication and Education Symposium. Tustin, CA. July 11, 2007.
221. Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer. Tennessee Oncology Educational Symposium. Franklin, TN. July 12, 2007.
222. Adjuvant Chemotherapy for HER-2 (+) Disease and Systemic Therapy for Relapsed Breast Cancer. NMCR Challenging Cases in Breast Cancer Symposium. Las Vegas, NV. July 14, 2007.
223. Hormone Therapy for Early and Advanced Breast Cancer. Community Oncology Forum. Pomona, CA. July 18, 2007.
224. Advances in Adjuvant Hormonal Treatment of Breast Cancer. 1ST Annual Asif A. Chaudhry, MD Lectureship. Cleveland Clinic Fairview Hospital. Cleveland, OH. September 10, 2007.
225. Breast Health Global Initiative. The Global Summit on International Breast Health Care – Implementation. Panelist – Early Detection Panel. Budapest, Hungary. October 1-4, 2007.
226. Update on Adjuvant Therapy for Breast Cancer. Santa Barbara Cancer Center Tumor Conference. October 17, 2007.
227. Adjuvant Therapy for Early Breast Cancer. Presbyterian Community Hospital Tumor Conference. Whittier, CA. October 30, 2007.
228. Adjuvant Therapy for Early Breast Cancer. Arcadia Methodist Tumor Conference. Arcadia, CA. November 1, 2007.
229. Update in the Treatment of Metastatic Breast Cancer. Orange County Community Oncology Forum. Santa Ana, CA. November 7, 2007.
230. Advances in Breast Cancer from a Global Perspective. California Cancer Registrars’ Association 34th Annual Meeting. Pasadena, CA. November 8, 2007.
231. Examining New Adjuvant Therapy Data in Early Breast Cancer. South Bay Community Oncology Forum. Seal Beach, CA. November 8, 2007.
232. Systemic Treatment of Metastatic Breast Cancer. NMCR Challenging Cases in Breast Cancer Meeting. San Francisco, CA. November 10, 2007.
233. Examining New Adjuvant Therapy Data in Early Breast Cancer. Glendale Memorial Hospital Tumor Conference. Glendale, CA. December 3, 2007.
234. Update in the Treatment of Metastatic Breast Cancer. Phoenix and Scottsdale Community Oncology Forum. Scottsdale, AZ. December 5, 2007.
235. Adjuvant Chemotherapy: From Receptors to Regimens to Real Patients. Case presentation. San Antonio Breast Cancer Symposium CME meeting. San Antonio, TX. December 14, 2007.
236. Evolving Chemotherapies and Hormonal Therapies for Metastatic Breast Cancer. Current Trends in Breast Cancer. Updates from the 2007 San Antonio Breast Cancer Symposium. A Physicians’ Education Resource CME Conference. Arlington, VA. January 12, 2008.
237. Breast Cancer Update. Internal Medicine Core Curriculum Lecture. Los Angeles County/USC Medical Center. Los Angeles, CA. January 15, 2008.
238. Breast Cancer Prognostic and Predictive Indicators. An American School of Oncology Breast Cancer Highlights CME series. Santa Monica, CA. January 26, 2008.
239. Breast Cancer Prognostic and Predictive Indicators. An American School of Oncology Breast Cancer Highlights CME series. New York, N.Y. February 9, 2008.
240. Adjuvant Therapy for Early Breast Cancer. Santa Barbara Oncology Medical Group Tumor Conference. Santa Barbara, CA. February 13, 2008.
241. Treatment Options for Early and Advanced Breast Cancer. Oncology Tumor Conference. Kaiser Permanente Panorama City. Panorama City, CA. February 14, 2008.
242. Breast Cancer Prevention and Diagnostics. An American School of Oncology Breast Cancer Highlights CME series. Chicago, IL February 16, 2008.
243. Advances in the Adjuvant Treatment of Early Breast Cancer. Scripps Cancer Center’s 28th Annual Conference: Clinical Hematology and Oncology. San Diego, CA. February 18, 2008.
244. Breast Cancer Prognostic and Predictive Indicators. A SABCS Update. Orange County Oncology community conference. Costa Mesa, CA. February 18, 2008.
245. Advances in the Therapy of Metastatic Breast Cancer. University of Oklahoma Post-San Antonio Breast Conference. Oklahoma City, OK. February 21, 2008.
246. Update on Hormone Therapy for Breast Cancer. Swedish Hospital Cancer Center Breast Cancer Conference. Seattle, WA. March 5, 2008.
247. Update on Hormone Therapy for Breast Cancer. Puget Sound Cancer Center Tumor Conference. Seattle, WA. March 5, 2008.
248. Evolving Chemotherapies and Hormonal Therapies for Metastatic Breast Cancer. Current Trends in Breast Cancer. Updates from the 2007 San Antonio Breast Cancer Symposium. A Physicians’ Education Resource CME Conference. Minneapolis, MN. March 8, 2008.
249. Update on Metastatic Breast Cancer. Mt. Diablo Hospital Cancer Conference. Concord, CA. March 19, 2008.
250. Update on Metastatic Breast Cancer. Stanford University Community Cancer Conference. Palo Alto, CA. March 19, 2008.
251. Breast Cancer Management: Updates, Advances, and New Options. Educational Concepts Group CME meeting. Santa Ana, CA. March 20, 2008.
252. Targeting HER-2 Positive Breast Cancer. San Jose Oncology Group Community Meeting. San Jose, CA. April 2, 2008.
253. Targeting HER-2 Positive Breast Cancer. Central California Oncology Forum. Pismo Beach, CA. April 7, 2008.
254. Debates in the Treatment of HER2+ Metastatic Breast Cancer – A Case Based Discussion. Inland Empire Oncology Forum. Ontario, CA. April 9, 2008.
255. Current Debates in the Treatment of HER2+ Metastatic Breast Cancer. NorthBay Cancer Center, Fairfield Breast Conference. Fairfield, CA. April 16, 2008.
256. Current Debates in the Treatment of HER2+ Metastatic Breast Cancer. Alta Bates Comprehensive Cancer Center, Providence Pavilion Family Resource Center Breast Conference. Oakland, CA. April 16, 2008.
257. Current Debates in the Treatment of HER2+ Metastatic Breast Cancer. CCE-Redwood Regional Group. Santa Rosa, CA. April 16, 2008.
258. Breast Cancer Management Updates, Advances, and New Options. Southern California Society of Health System Pharmacists Annual meeting. Beverly Hills, CA. May 3, 2008.
259. Controversies in Adjuvant Hormonal Therapy. Anchorage, Alaska Oncology Symposium. Anchorage, AK. May 14, 2008.
260. Updates in Management of Breast Cancer. Alaska Providence Hospital Tumor Conference. Anchorage, AK. May 15, 2008.
261. Advances in the Therapy of Metastatic Breast Cancer. Tacoma Community Oncology Forum. Tacoma, WA. May 20, 2008.
262. Breast Cancer. A Post ASCO 2008 Update. North Shore Long Island Jewish Health System Annual Post-ASCO Symposium. Roslyn, NY. June 12, 2008.
263. Controversies in Adjuvant Hormonal Therapy. Loma Linda University Grand Rounds. Loma Linda, CA. June 13, 2008.
264. Controversies in Adjuvant Hormonal Therapy and ASCO 2008 Update. Orange County Tumor Conference. Costa Mesa, CA. June 26, 2008.
265. Advances in the adjuvant treatment of early breast cancer. Hollywood Presbyterian Medical Center Grand Rounds, Hollywood, CA, 7/9/2008.
266. Targeted therapy for breast cancer: Avastin and Herceptin. Los Angeles Oncology Forum, Los Angeles, CA, 7/23/2008.
267. Adjuvant therapy for early breast cancer. Internists, Oncologists Tumor Forum, Phoenix, AZ, 9/10/2008.
268. Understanding the treatment paradigm in postmenopausal breast cancer. Southwest Hematology Oncology Tumor Forum, Scottsdale, AZ, 9/10/2008.
269. Evolving strategies in metastatic breast cancer. UCSF Community Oncology Forum, INCE CME Meeting, San Francisco, CA, 9/17/2008.
270. Monitoring and managing the cardiotoxicity of systemic therapeutic agents. 14th Perspectives in Breast Cancer Symposium, Brooklyn, NY, 9/26/2008.
271. Breast cancer highlights from the 2008 ASCO and ASCO Breast Meetings. 14th Perspectives in Breast Cancer Symposium, Brooklyn, NY, 9/27/2008.
272. Updates in the management of HER-2 positive breast cancer. Kaiser Permanente Riverside Oncology Forum, Riverside, CA, 9/30/2008.
273. Current debates in the treatment of HER2+ metastatic breast cancer. Olympia Washington Oncology Forum, Olympia, WA, 10/1/2008.
274. Inside breast cancer: current and emerging treatment options. Are we making progress? Providence Saint Joseph Medical Center Grand Rounds, Burbank, CA, 10/2/2008.
275. Current debates in the treatment of HER2+ metastatic breast cancer. White Memorial Hospital Cancer Conference, Los Angeles, CA, 10/15/2008.
276. Evolving strategies in metastatic breast cancer. Seminars in Oncology Comprehensive Care Network, Santa Monica, CA, 10/21/2008.
277. Breast cancer management: updates, advances and new options. Fresno Oncology Symposium, Fresno, CA, 10/22/2008.
278. New developments in adjuvant and neoadjuvant chemotherapy. Current Trends in Breast Cancer 2009, Physician’s Education Resource CME Meeting, Seattle, WA, 1/10/2009.
279. Novel biologic agents with clinical promise: inhibitors of angiogenesis, mTOR, and other emerging signaling pathways. Current Trends in Breast Cancer 2009, Physician’s Education Resource CME Meeting, Seattle, WA, 1/10/2009.
280. Adjuvant therapy for early breast cancer. Update of the 31st Annual SABCS Meeting, Fountain Valley Cancer Center Conference, Santa Ana, CA, 1/15/2009.
281. Cardiovascular disease and cognitive impairment. Breast Cancer Survivorship, Wendy and Emery Reves International Biennial Breast Cancer Symposium, UT Southwestern University Medical Center, Dallas, TX, 2/7/2009.
282. Targeted options for the patient with breast cancer. 29th Annual Clinical Hematology and Oncology Conference, Scripps Cancer Center, San Diego, CA, 2/17/2009.
283. Breast cancer: current and emerging treatment options. Providence Holy Cross Medical Center Grand Rounds, Mission Hills, CA, 3/3/2009.
284. Management of bone-related issues in breast cancer – which therapy for which patient? 15th Annual NOCR Meeting, Las Vegas, NV, 3/13/2009.
285. Adjuvant therapy for early breast cancer. Cottage Hospital Tumor Conference, Santa Barbara, CA, 4/21/2009.
286. Breast cancer update with emerging therapies. Cancer Clinics of Excellence Tumor Conference, Macon, GA, 5/5/2009.
287. Adjuvant therapy for early breast cancer. Roseville Oncology Tumor Conference, Roseville, CA, 5/13/2009.
288. Early breast cancer: a targeted therapy approach. David King Memorial Lectureship, Banner Good Samaritan Medical Center, Phoenix, AZ, 5/14/2009.
289. Appropriate Management of Small Breast Cancers. 15th Annual Perspectives in Breast Cancer. Imedex CME Symposium. New York, NY. August 22, 2009.
290. New Frontiers in Managing Metastatic Breast Cancer. Roche Lectureship at the Annual Meeting of the Cancer Institute of New Jersey Oncology Group. New Brunswick, NJ. October 20, 2009.
291. Assessing and Managing Breast Cancer Risk: Environmental and Genetic Factors. Breast Cancer Update: State-of-the-Art for the Primary Physician. University of Southern California. Los Angeles, CA. December 5, 2009.
292. Novel Biologic Agents with Clinical Promise in Breast Cancer: Current Trends in Breast Cancer CME meeting. Physicians Education Resource CME Symposium. Pasadena, CA. January 30, 2010.
293. Her-2: What’s New? Scripps Cancer Center 30th annual Conference: Clinical Hematology & Oncology. San Diego, CA. February 15, 2010.
294. Preventive Medicine, Cancer Screenings, Part II: Breast Cancer and Other Screening Controversies. San Diego Academy of Family Physicians’ Postgraduate Symposium: Family Medicine Update 2010. San Diego, CA. June 26, 2010.
295. 2010 ASCO Review: An Update on Breast Cancer. Stowers Institute for Medical Research. The University of Kansas Medical Center Symposium. Kansas City, MO. July 17, 2010.
296. Advances in Breast Cancer Diagnosis and Treatment. Torrance Memorial Hospital Grand Rounds. Torrance, CA. August 11, 2010.
297. Breast Cancer: Current and Emerging Treatment Options. Providence Holy Cross Medical Center Grand Rounds. Mission Hills, CA. October 5, 2010.
298. Focus on Relapsed/Refractory Metastatic Breast Cancer. A Physician’s Education Resource CME community meeting. Newport Beach, CA. October 19, 2010.
299. Debate: Bisphosphonates Should be Routinely Used to Prevent Disease Recurrence in Women with Early Stage Breast Cancer; Pro. Northwestern University 12th Annual Lyn Sage Breast Cancer Symposium. Chicago, IL. October 31, 2010.
300. Breast Cancer Risk and Prevention. Modern Approaches in Prophylaxis of Oncologic Diseases in Women. St. Petersburg State University. St. Petersburg, Russia. December 11, 2010.
301. Protecting Bone Health in Patients with Breast and Prostate Cancer. Albert Einstein University CME Symposium. San Francisco, CA. January 13, 2011.
302. Novel Biologic Agents with Clinical Promise. Current Trends in Breast Cancer: Updates from the 2010 San Antonio Breast Cancer Symposium. A Physicians Education Resource CME meeting. Pasadena, CA. January 29, 2011.
303. Hormone Receptor-Positive Breast Cancer. 17th Annual NOCR CME Meeting. Albert Einstein College of Medicine. Las Vegas, NV. February 12, 2011.
304. Bisphosphonates in Early Breast Cancer. Scripps Cancer Center’s 31st Annual Conference. La Jolla, CA. February 22, 2011.
305. Breast Cancer: Current and Emerging Treatment Options. Ventura County Medical Center Surgical Conference. Ventura, CA. February 23, 2011.
306. Gene Array Assays in Lymph Node Positive Breast Cancer. 17th Annual Perspectives in Breast Cancer Symposium. New York, NY. August 13, 2011
307. Inflammatory Breast Cancer. 17th Annual Perspectives in Breast Cancer Symposium. New York, NY. August 13, 2011.
308. The Dilemma of Metastatic Breast Cancer. Practical Strategies for the Management of Metastatic Breast Cancer. 2011 Breast Cancer Symposium. An Educational Concepts Group CME Symposium. San Francisco, CA. September 8, 2011.
309. What’s on the Horizon for Metastatic Breast Cancer? Practical Strategies for the Management of Metastatic Breast Cancer. 2011 Breast Cancer Symposium. An Educational Concepts Group CME Symposium. San Francisco, CA. September 8, 2011.
310. Screening and Prevention Across the Risk of Continuum. 7th Annual Oncology Congress. Evolving Therapies, Personalized Treatments, Improved Patient Outcomes. San Francisco, CA. October 14, 2011.
311. Considerations in the Management of Triple Negative and Hormone-Refractory Metastatic Breast Cancer. Metastatic Breast Cancer: Updates in Clinical Practice. A Medicom, Inc. CME Symposium. Houston, TX. October 15, 2011.
312. Breast Cancer Risk and Gynecologic Effects of Treatment. 55th Annual T. Hart Baker, MD OB/GYN Symposium. Kaiser Permanente Medical Group. Santa Barbara, CA. November 12, 2011.
313. Early Stage Breast Cancer: An Algorithm for Personalized Therapy and Long-Term Monitoring for Relapse. 18th Annual NOCR Meeting. Las Vegas, Nevada. February 10, 2012.
314. Genomics and Decision-Making in Breast Cancer. Tarzana Hospital Tumor Board. Tarzana, CA. February 15, 2012.
315. Novel Approaches to Breast Cancer-Related Bone Disease. 13th Annual Palm Beach Cancer Symposium. Hollywood, FL. March 31, 2012.
316. Can Dual Blockade Replace Chemotherapy for HER2-positive Breast Cancer? 13th Annual Palm Beach Cancer Symposium. Hollywood, FL. March 31, 2012.
317. Breast Cancer. Highlights from the 2012 Annual Meeting of ASCO. Imedex CME meeting. San Francisco, CA. July 21, 2012.
318. Growth Factor Pathways in Hormone Resistant Breast Cancer. 18th Annual Perspectives in Breast Cancer Symposium. New York, NY. August 18, 2012.
319. How I Manage Early Stage HER2+ Breast Cancer. 18th Annual Perspectives in Breast Cancer Symposium. New York, NY. August 18, 2012.
320. ER+ Breast Cancer: New Pathways to Improved Outcomes. Community Memorial Hospital Tumor Conference. Ventura, CA. October 31, 2012.
321. ER+ Breast Cancer: New Pathways to Improved Outcomes. Educational Concepts Group Community conference. Newport Beach, CA. November 1, 2012.
322. Modifiable Risk Factors in Children and Adolescents for Prevention of Cancer. XVII Summit of Russian Pediatricians. Moscow, Russia. February 15, 2013.
323. Breast Cancer Prevention. The State of Personalized Medicine and Modern Aspects of Breast Cancer Screening and Prevention Symposium. Tashkent, Uzbekistan. February 18, 2013.
324. Systemic Therapy for HER-2 Positive Breast Cancer. 19th Annual NOCR meeting. Albert Einstein College of Medicine. Las Vegas, NV. March 15, 2013.
325. Bone-Directed Therapy in Breast Cancer. 19th Annual NOCR meeting. Albert Einstein College of Medicine. Las Vegas, NV. March 15, 2013.
326. Breast Cancer: How to Interpret the Different Screening Recommendations. 41st Annual USC Diagnostic and Therapeutic Skills in Internal Medicine. Maui, Hawaii. March 19, 2013.
327. When Do You Refer a Patient for Cancer-Related Genetic Counseling? 41st Annual USC Diagnostic and Therapeutic Skills in Internal Medicine. Maui, Hawaii. March 19, 2013.
328. Prostate Cancer Screening – Does Anyone Benefit? 41st Annual USC Diagnostic and Therapeutic Skills in Internal Medicine. Maui, Hawaii. March 19, 2013.
329. Updates on Screening for Lung and Cervical Cancer. 41st Annual USC Diagnostic and Therapeutic Skills in Internal Medicine. Maui, Hawaii. March 20, 2013.
330. Considerations in the Management of Triple Negative Metastatic Breast Cancer. Metastatic Breast Cancer: Integrating Clinical Findings into Practice. MediCom Worldwide CM Meeting. Washington, DC. April 6, 2013.
331. Advancing Our Understanding of the Role of Genomics in the Treatment of Breast Cancer. Individualized Treatment Strategies for Adjuvant Systemic Therapy of Invasive Early-stage Breast Cancer. Third Annual Asia-Pacific Cancer Leaders Forum. Singapore. July 13, 2013.
332. Duration of Adjuvant Endocrine Therapy: What Have ATLAS and aTTom Taught Us? 12th International Congress on the Future of Breast Cancer PER CME meeting. Huntington Beach, CA. July 18, 2003.
333. Personalized Medicine for Breast Cancer: It’s a New Day! Scott Woods Memorial Lecture. Annual Meeting of the Midwest Surgical Association. Traverse City, MI. July 29, 2013.
334. State of the Art Management of HER2-Positive Metastatic Breast Cancer. Providence St. Joseph’s Medical Center Grand Rounds. Burbank, CA. October 8, 2013.
335. Revolutionizing the Treatment Strategy for Recurrent Breast Cancer. Idaho Society of Clinical Oncology Annual Meeting. Boise, ID. November 9, 2013.
336. San Antonio Breast Cancer Symposium Perspectives. USC Norris Comprehensive Cancer Center: Radiation Oncology Breast Cancer Symposium. Los Angeles, CA. January 26, 2014.
337. Competing Risks of Low-Risk Breast Cancer. Scripps’ 34th Annual Conference: Clinical Hematology and Oncology 2014. February 17, 2014.
338. Current Advances in Breast Cancer Treatment. Providence Holy Cross Medical Center CME medical conference. Mission Hills, CA. February 18, 2014.
339. Highlights from the San Antonio Breast Cancer Symposium: Screening and Prevention. 20th Annual NOCR Meeting. Las Vegas, NV. February 28, 2014.
340. Management of HER2 Overexpressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic Settings – Optimal Utilization of Available Agents and Clinical Trials. 20th Annual NOCR Meeting. Las Vegas, NV. February 28, 2014.
341. Personalized Medicine for Breast Cancer: It’s a Brand new Day! Cottage Health System’s 7th Oncology Nursing Symposium. Santa Barbara, CA. October 24, 2014.
342. San Antonio Breast Cancer Symposium Update. 2nd Annual USC Multidisciplinary Breast Cancer Symposium. Los Angeles, CA. January 17, 2015.
343. HER-2 Directed Therapy in Breast Cancer. Scripps’ 35th Annual Conference: Clinical Hematology and Oncology. San Diego, CA. February 17, 2015.
344. Optimal Management of the Pre-menopausal Patient with Estrogen Receptor-Positive Breast Cancer. Scripps’ 35th Annual Conference: Clinical Hematology and Oncology. San Diego, CA. February 17, 2015.
345. Optimal Multidisciplinary Treatment of Breast Cancer. USC Keck School of Medicine Dean’s Clinical lecture series. Los Angeles, CA March 4, 2015.
346. One Physician’s Journey in Balancing Work with Cancer Patients. Fifteenth Annual USC Psychosocial Seminar. Los Angeles, CA. March 12, 2015.
347. Adjuvant Therapy of Breast Cancer. 21st Annual NOCR Meeting. Las Vegas, NV. March 13, 2015.
348. Breast Cancer – The Road Forward. A SABCS and ASCO update. Kaiser Permanente Inaugural Multi-Disciplinary Oncology Symposium. Long Beach, CA. June 13, 2015.
349. Tailored Medicine for Breast Cancer: It’s a New Day. Cancer de Mama 2015 Avancos e Perspectivas. Hospital Sirio-Libanes. Sao Paulo, Brazil. June 26, 2015.
350. Individualizing the Treatment of Early Stage Breast Cancer. Understanding the Patient’s Tumor Biology. Cancer de Mama 2015 Avancos e Perspectivas. Hospital Sirio-Libanes. Sao Paulo, Brazil. June 26, 2015.
351. First, a Lump in a Breast: Personalized Medicine for Breast Cancer. The 24th Annual Cancer Surveillance Program Educational Symposium. Los Angeles, CA. August 7, 2015.
352. Improving Outcomes in HER2neu Early and Advanced Breast Cancer. IMPANGO – Making Africa Paramount in Global Oncology. Naivasha, Kenya. September 12, 2015.
353. Endocrine Therapy for DCIS. 17th Annual Lynn Sage Breast Cancer Symposium. Chicago, IL. November 1, 2015.
354. Current and Future Treatment of HER2-Positive Breast Cancer: Expert Advice for Clinicians. University of Texas Health Science Center at San Antonio; CTRC – Institute for Drug Development Oncology Conference. San Antonio, TX. November 18, 2015.
355. Best of San Antonio Breast Cancer Symposium. 3rd Annual USC Multi-Disciplinary Breast Cancer Symposium. Los Angeles, CA. January 30, 2016.
356. Neoadjuvant Therapy for Breast Cancer – Implications for Future Surgery. Santa Barbara Cottage Hospital Surgical Grand Rounds. Santa Barbara, CA. June 8, 2016
357. Update in Recurrent and Advanced Breast Cancer. 59th Annual Raymond M Kay, MD Internal Medicine Symposium. Anaheim, CA. September 30, 2016
358. Personalized Medicine for Breast Cancer. It’s a New Day! Sri Lanka Medical Association of North America Symposium. Los Angeles, CA. October 1, 2016.
359. Best of ASCO and SABCS 2016. 4th Annual USC Multi-Disciplinary Breast Cancer Symposium. Los Angeles, CA. January 28, 2017.

**H. Publications:**

# Refereed Journal Articles:

1. Shani J1, Bertram J, **Russell C**, Dahalan R, Chen DC, Parti R, Ahmadi J, Kempf RA, Kawada TK, Muggia FM,. Noninvasive monitoring of drug biodistribution and metabolism: Studies with intraarterial Pt-195m-Cisplatin in Humans*. Cancer Research* 49: 1877, 1989. PMID: 2924326
2. Grunberg SM, Stevenson LL, **Russell CA,** McDermed JE. Dose Ranging Phase I Study of the Serotonin Antagonist GR38032F for Prevention of Cisplatin-Induced Nausea and Vomiting. *Journal of Clinical Oncology* 7:1137-1141, 1989. PMID: 2526864
3. Skinner DG, Daniels JR, **Russell CA**, Lieskovsky G, Boyd SD, Krailo M, Groshen S. Adjuvant Chemotherapy Following Cystectomy Benefits Patients with Deeply Invasive Bladder Cancer. *Seminars in Urology* 8(4):279-284, 1990. PMID: 2526864
4. Muggia FM, **Russell CA.**  New Chemotherapies for Ovarian Cancer Systemic and Intraperitoneal Podophyllotoxins. *Cancer* 67:226-230, 1991. PMID: 1984824
5. Skinner DG, Daniels JR**, Russell CA**, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J Krailo M, Groshen S. The Role of Adjuvant Chemotherapy Following Cystectomy for Invasive Bladder Cancer: A Prospective Comparative Trial. *J Urol* 145:459-467, 1991. PMID: 1997689
6. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A**, Russell CA**, Lucci L, Stevenson LL. Treatment of Unresectable Meningiomas with the Anti-progestational Agent Mifepristone. J Neurosurg 74:861-866, 1991. PMID: 2033444
7. Muggia FM, Chan KK, **Russell C**, Colombo N, Speyer JL, Sehgal K, Jeffers S, Sorich J, Leichman L, Beller U, and Beckman EM. Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2’-deoxyuridine. *Cancer Chemotherapy and Pharmacology* 28:241-250, 1991. PMID: 1831736
8. Muggia FM, LePoidevin E, Jeffers S**, Russell C**, Boswell W, Morrow CP, et al. Intraperitoneal Therapy for Ovarian Cancer: Analysis of Fluid Distribution by Computerized tomography. *Annals of Onc* 3:149-154, 1992. PMID: 1606086
9. Muggia FM, Groshen S, **Russell C**, Jeffers S, Chen S-C, Schlareth J, Curtin J, Morrow CP. Intraperitoneal Carboplatin and Etoposide for Persistent Epithelial Ovarian Cancer: Analysis of Results by Prior Sensitivity to Platinum-Based Regimens. *Gynecol Oncol* 50:232-238, 1993. PMID: 8375739
10. Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical Resection in Patients with Non-seminomatous Germ Cell Tumor Who Fail to Normalize Their Serum Tumor Markers After Chemotherapy. *Urology* 43:74-80, 1994.
11. Uziely B, Groshen S, Jeffers S, Morris M, **Russell C**, Roman L, Muderspach L, Muggia F. Paclitaxel (Taxol) in Heavily Pretreated Ovarian Cancer: Antitumor Activity and Complications. *Ann Oncol* 5:827-833, 1994. PMID: 7848885
12. Turrill M, Spicer DV, Kelley AS, Herman RL, **Russell CA**, Muggia FM. Phase II Clinical Trial of Carboplatin, Ifosfamide with Oral Mesna for Metastatic Breast Carcinoma. *Cancer Invest* 13(2): 160-164, 1995. PMID: 7874569
13. **Russell CA**, Green SJ, O’Sullivan J, Hynes HE, Budd GT, Congdon JE, Martino S, Osborne CK. Megestrol acetate and amino glutethimide/ hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer. A Southwest Oncology Group phase III trial. *J Clin Onc* 15(7): 2494-2501, 1997. PMID: 9215817
14. Hochberg F., Prados M., **Russell C**, Weissman D, Evans R, Cook P, Burton G, Eisenberg PD, Valenzuela R, Verkh L. Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study*. J Neuro-Oncology* 32(1):45-55, 1997. PMID: 9049862
15. Chalabian J, Formenti S, **Russell C**, Pearce J, Dunnington G. Comprehensive needs assessment of clinical breast evaluation skills of primary care residents. *Annals of Surgical Oncology* 5(2):166-72, 1998. PMID: 9527270
16. Haas GP, Blumenstein BA, Gagliano RG, **Russell CA**, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: A Southwest Oncology Group study. *J Urology* 161(6):1823-5, 1999. PMID: 10332445
17. Yang X, Uziely B, Groshen S, Lukas J, Israel V, **Russell C**, Dunnington G, Formenti S, Muggia F, Press M. MDR1 gene expression in primary and advanced breast cancer*. Lab Invest* 79:271-280, 1999., PMID: 10092063
18. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heron D, Rogers L, O’Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, **Russell C**, Shapiro W, Swinnen L, Howell SB. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. *British Journal of Cancer* 84(2): 157-63, 2001. PMID: 11161370
19. Silverstein MJ, Parker R, Grotting JC, Cote RJ, **Russell CA**. Ductal carcinoma in situ (DCIS) of the breast: diagnostic and therapeutic controversies*. J American College of Surgeons* 192(2): 19-214, 2001. PMID: PMID: 11220720
20. Jaeckle, KA, Batchelor T, O’Day SJ, Phuphanich S, New P, Lesser, G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers, L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, **Russell C**, Swinnen L, Howell SB. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment solid tumor neoplastic meningitis*. J Neuro-Oncology* 57(3):231-9, 2002. PMID: 12125986
21. **Russell CA**. Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cm. *Curr Women’s Health Reports* 2(2):134-139,2002. PMID: 12116603
22. Toppmeyer D1, Seidman AD, Pollak M, **Russell C**, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD. Safety and efficacy of the multidrug resistance inhibitor Incel in combination with paclitaxel for advanced breast cancer refractory to paclitaxel*. Clin Cancer Res* 8(3):670-8, 2002. PMID: 11895894
23. Woo CS, **Russell CA**, Silverstein MJ. Ductal carcinoma in situ: controversies in treatment options. Women’s Oncol Rev 2:371-84, 2002. PMID: 15735580
24. **Russell CA**. Adjuvant Systemic therapy for lymph node-negative breast cancer less than or equal to 1 cm. *Curr Oncology Reports* 5(1):72-7, 2003. PMID: 12493154
25. Lyman GH, Green SJ, Ravdin PM, Geyer Jr CE, **Russell CA**, Balcerzak SP, Thomas Budd G, Martino S;A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer. *Br Can Res Trt* 85:143-150, 2004. PMID: 15111772
26. Li HC, **Russell CA.** Gemcitabine and platinum-based chemotherapy in metastatic breast cancer. Oncology 18 (No.14, Suppl 12):17-22, 2004. PMID: 15685821
27. Ell K, Sanchez K, Vourlekis B, Lee PJ, Dwight-Johnson M, Lagomasino I, Muderspach L, **Russell C**. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. *J Clin Oncol* 23(13)3052-3060, 2005. PMID: 15860863
28. Dewilde LF**, Russell C**. The “Welcome to Medicare” physical: a great opportunity for our seniors. *CA Cancer J Clin* 54(6)292-294, 2004.PMID: 15537573
29. Grunberg SM, Weiss MH, **Russell CA,** Spitz IM et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. *Cancer Investigation* 24:727-733, 2006. PMID: 17162554
30. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, **Russell CA** (for the American Cancer Society Breast Cancer Advisory Group). American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. *CA Cancer* *J Clin* 57:75-89, 2007.
31. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, **Russell C**, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer*. J Clin Oncol* 27(13):2163-9, 2009. PMID: 19307510
32. Ell K, Vourlekis B, Xie B, Nedjat-Haiem FR, Lee PJ, Muderspach L, **Russell C**, Palinkas LA. Cancer treatment adherence among low-income women with breast or gynecologic cancer: a randomized controlled trial of patient navigation. *Cancer* 115(19):4606-15, 2009. PMID: 19551881
33. Liu SV, Melstrom L, Yao K, **Russell CA**, Sener SF. Neoadjuvant therapy for breast cancer. *J Surg Oncol* 101:283-291, 2010. PMID: 20187061
34. Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, **Russell CA**, Royce ME, Perez EA, Lew D, and Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. *J Clin Oncol* 29:1014-1021, 2011. PMID: 21220618
35. Seidman AD1, Brufsky A, Ansari RH, Hart LL, Stein RS, Schwartzberg LS, Stewart JF, **Russell CA**, Chen SC, Fein LE, De La Cruz Vargas JA, Kim SB, Cavalheiro J, Zhao L, Gill JF, Obasaju CK, Orlando M, Tai DF. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. *Ann Oncol* 22(5):1094-1101, 2011.
36. **Russell C.** The role of albumin-bound paclitaxel in metastatic breast cancer. Clinical Advances in Hematology and Oncology 9(6):469-71, 2011. PMID: 21841747
37. Schmale I, Liu S, Rayhanabad J, **Russell CA**, Sener SF. Ductal Carcinoma In Situ (DCIS) of the Breast: Perspectives on biology and controversies in current management. *J Surg Onc* 105;212-220, 2012. PMID: 21751217
38. Somlo G. Martel CL. Lau SK. Frankel P. Ruel C. Gu L. Hurria A. Chung C. Luu T. Morgan R Jr. Leong L. Koczywas M. McNamara M. **Russell CA**. Kane SE. A phase I/II prospective single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV Her-2 positive metastatic breast cancer. *Breast Cancer Research and Treatment* 131(3):899-906, 2012. PMID: 22042372
39. Glück S, **Russell C**, O'Shaughnessy J, McKenna EF, Hu S, Odom D, Blum JL. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: Results of an exploratory analysis. *Breast* 22(6):1087-1093, 2013. PMID: 24095220
40. **Russell CA.** Personalized medicine for breast cancer: it is a new day! *Am J Surg* 207;321-325, 2014. PMID: 24581758
41. **Russell CA**. Molecular profiling for DCIS. *Clin Adv Hematol Oncol* 12(9):611-3, 2014. PMID: 25654484
42. Wecsler JS1, Tereffe W, Pedersen RC, Sieffert MR, Mack WJ, Cui H, **Russell CA**, Woods RR, Viscusi RK, Sener SF, Lang JE.. Lymph node status in inflammatory breast cancer. *Breast Cancer ResTreat* 151(1):113-20, 2015. PMID: 25846421
43. Wu AH, Spicer D, Garcia A, Tseng CC, Hovanessian-Larsen L, Sheth P, Martin SE, Hawes D, **Russell C**, MacDonald H, Tripathy D, Su MY, Ursin G, Pike MC. Double-blind randomized 12-month soy intervention had no effects on breast MRI fibroglandular tissue density or mammographic density. *Cancer Prev Res* 8(10):942-51, 2015. PMID:[26276750](http://www.ncbi.nlm.nih.gov/pubmed/26276750)
44. Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, **Russell CA**, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005*. J Clin Oncol* 33:4093-4098, 2015. PMID: 26527781
45. Koulisis N, Moysidis SN, Olmos de Koo LC, **Russell CA**, Kashani AH. The tipping point: Tamoxifen toxicity, central serous chorioretinopathy, and the role of estrogen and its receptors. *Am J Ophthalmol* Case Rep 3:8-13, 2016. PMID:29503899
46. Piatek CI, Ji L, Kaur, C, **Russell CA**, Tripathy D, Church T, Sposto R, Sener SF, Garcia AA. Value of routine staging imaging studies for patients with stage III breast cancer. *J Surg Oncol* 114(8):917-921, 2016. PMID:27642105
47. Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz M, **Russell C,** et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer. Clin Cancer Res 23(19):5687-5695, 2017. Doi: 10.1158/1078-0432.CCR-17-0900
48. Mamounas EO, **Russell CA**, Lau A, Turner MP, Albain KS. Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era. *NPJ Breast* 4:1-6, 2018. PMID:30155517
49. Bello DM, **Russell C**, McCullough D, Tierno M, Morrow M. Lymph node status in breast cancer does not predict tumor biology. *Ann Surg Oncol* 25(10):2884-2889, 2018.
50. Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, **Russell C**, Winer EP, Partridge AH. Prognostic impact of the 21-gene Recurrence Score assay among women with node-negative and node-positive ER-positive/HER2-negative breast cancer. [*J Clin Oncol* 38(7):725-733, 2020. DOI: 10.1200/JCO.19.01959.](https://ascopubs.org/doi/abs/10.1200/JCO.19.01959)
51. Wecsler J, Jeong YJ, Raghavendra AS, Mack WJ, Tripathy D, Yamashita MW, Sheth PA, Larsen LH, **Russell CA**, MacDonald H, Sener SF, Lang JE. Factors associated with MRI detection of occult lesions in newly diagnosed breast cancers. *J Surg Oncol* 121:589-598, 2020. DOI: 10.1002/jso.25855.
52. Chang GJ, You YNY, **Russell CA**, Tierno MB, Turner M, Bennett JP, Lau A, Hochster HS. Young-onset colon cancer and recurrence risk by gene expression. [*J Natl Cancer Inst.*](https://www.ncbi.nlm.nih.gov/pubmed/32040172) 2020 Feb 10. pii: djaa019. DOI: 10.1093/jnci/djaa019.
53. Sella T, Gelber SI, Poorvu PD, Kim HJ, Dominici L, Guzman-Arocho YD, Collins L, Ruddy KJ, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Snow C, Jakubowski DM, **Russell CA**, Winer EP, Rosenberg SM, Partridge AH. Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. *Breast Cancer Res Treat*. 2020 Nov 4. doi: [10.1007/s10549-020-05989-5](https://doi.org/10.1007/s10549-020-05989-5). Epub ahead of print. PMID: [33150547](https://pubmed.ncbi.nlm.nih.gov/33150547/).
54. Kantor O, King TA, Shak S, **Russell CA**, Giuliano AE, Hortobagyi GN, Burstein HJ, Winer EP, Dey T, Sparano JA, Mittendorf EA. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. *J Natl Cancer Inst.* 2021 May 19:djab095. doi: 10.1093/jnci/djab095. Epub ahead of print. PMID: 34010423.
55. Bloom JA, Sekigami Y, Young R, Macera L, **Russell CA**, Cao Y, Buchsbaum RJ, Naber SP, Chatterjee A. Discordance in Oncotype DX Breast Recurrence Score® Results for Bilateral Breast Cancer. *Ann Surg Oncol*. 2021 Jul 9. doi: 10.1245/s10434-021-10387-2. Epub ahead of print. PMID: [34241750](https://pubmed.ncbi.nlm.nih.gov/34241750/).
56. Kantor O, Burstein HJ, King TA, Shak S, **Russell CA,** Giuliano AE, Hortobagyi GN, Winer EP, Korde LA, Sparano JA, Mittendorf EA. Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx. *Ann Surg Oncol.* 2022 Jul 27. doi: 10.1245/s10434-022-12225-5. Epub ahead of print. PMID: 35900648
57. Taylor C, Meisel J, Foreman AJ, **Russell C**, Bandyopadhyay D, Deng X, Floyd L, Zelnak A, Bear H, O'Regan R. Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. *Breast Cancer Res Treat*. 2023 Mar 10. doi: 10.1007/s10549-023-06890-7. Epub ahead of print. PMID: 36897465
58. Berdunov V, Laws E, Cuyun Carter G, Luo R, **Russell C**, et al. The budget impact of utilizing the Oncotype DX Breast Recurrence Score® test from a US healthcare payer perspective. J Med Econ. 2023 Jul 19. doi: [10.1080/13696998.2023.2235943](https://doi.org/10.1080/13696998.2023.2235943). Epub ahead of print.

**Editorials**

1. Sener S and **Russell C**. The Crux of the Confusion About Screening Mammograms. *J Surg Oncol* 102:547-548, 2010.

**Chapters**

1. Daniels JR, Skinner DG, **Russell CA**, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto S, Krailo M, Groshen S. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. Adjuvant Chemotherapy of Cancer VI, Salmon SE, ed. WB Saunders, Philadelphia, 1990.

2. **Russell CA**. A case study in breast cancer. Clinical Simulations in Cancer Care. Vol 1, Peter Wiernik, ed. Medical Age Publishing, Norwalk, CT. April 1996.

1. Israel VK, **Russell CA**, Dolkar D, Streeter O. Recurrent mediastinal nonseminomatous germ cell malignancy. Tumor Board Case Management. DP Winchester, et al, Eds. Lippincott-Raven Publishers, 1997.
2. **Russell CA**. Adjunctive Systemic Therapy for Breast Cancer. Breast Care: A Clinical Guidebook for Women’s Primary Health Providers. WH Hindle, Ed. Springer-Verlag Publishers, New York, NY, 1999.
3. **Russell CA** and Lee E. The role of adjuvant therapy in node-negative breast cancer patients. Surgical Oncology. Multidisciplinary approach to difficult problems. Silberman H and Silberman AW, Eds. Oxford University Press Inc., New York, NY, 2002.
4. **Russell CA**. Tamoxifen and/or Hormone Replacement Therapy after Treatment for Ductal Carcinoma in Situ. Ductal Carcinoma in Situ of the Breast. Silverstein MJ, Ed. Lippincott Williams&Wilkins Publishers, Philadelphia, PA, 2002
5. Box BA and **Russell CA**. Breast Cancer. Manual of Clinical Oncology. Casciato DA, Ed. Lippincott Williams &Wilkins Publishers. Philadelphia, PA, 2004.
6. Liu SV and **Russell CA**. Medical Treatment for Bone Metastases. 5th Edition Diseases of the Breast. Harris JR, Morrow M, Lippman ME, and Osborne CK, Eds. Wolters Kluwer Health Publishers, Philadelphia, PA, 2014.

**Abstracts**

1. Daniels JR, **Russell C**, Skinner DG, Lieskovsky G, Boyd SE, Krailo M, & Klimaszewski A. Malignant germinal neoplasms: intensive weekly chemotherapy with cisplatin, vincristine, bleomycin, and etoposide. Proc Am Soc Clin Onc 6:1987.

2. **Russell CA**, Daniels JR, Skinner DG, Lieskovsky G, Boyd SE Krailo M, Klimaszewski A. Malignant germinal neoplasms: adjuvant therapy with intensive weekly chemotherapy (meeting abstract). Fifth International Conference on the Adjuvant Therapy of Cancer. March 1987.

3. Kitsigianis GA, Muggia FM, Grunberg SM, **Russell CA**, Daniels JR, O’Leary DP. Monitoring for cisplatin-induced vestibular toxicity: Prospective use of the vestibular autorotation test in clinical trials (meeting abstract). First International Symposium on Organ Directed Toxicities of Anticancer Drugs, Burlington, VT June 1987.

4. Sehgal K, **Russell CA**, et al. Phase I trial of intraperitoneal (IP) 5-Fluoro- 2’deoxyuridine (FUdR). Proc AACR 1988.

5. Wolf W, Shani J, Parti R, Kawada T, Kempf RA, **Russell C**, Muggia FM, Bertram J, Chen DCP, Siegel ME, Ahmadi J. Noninvasive monitoring of drug biodistribution and metabolism: Studies with Pt-195m-Cisplatin. Proc AACR 29:186, 1988.

6. Daniels JR, **Russell CA**, Skinner DJ, Muggia FM, et al. Recent advances in the treatment of testicular and ovarian cancer. (meeting abstract and presentation). Perugia International Cancer Conference II, Perugia, Italy June 1989.

7. Gruber ML, Prados M, **Russell C**, Hochberg F, Cook P, Weissman D, Evans R, Burton G, Allen D, Branon R. Phase I/II Study of Fluosol/oxygen in combination with BCNU in malignant brain glioma. Proc AACR 31:190, 1990.

8. Daniels JR, Skinner DG, **Russell CA**, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. Proc ASCO 9:506, 1990

9. Grunberg SM, Weiss M, Spitz I, **Russell C**, Zaretsky S. Treatment of meningioma with the oral antiprogestational agent Mifepristone (RU486). Proc ASCO 10:371, 1991.

10. Tulpule A, Muggia F, **Russell C**, Jeffers S, Schlaerth J, Curtin J, Morrow CP. Intraperitoneal (IP) carboplatin (CB) plus etoposide (VP) for persistent epithelial ovarian cancer (EOC) after platinum-based regimens. Proc ASCO 10:621, 1991.

11. Uziely B, Groshen S, **Russell C**, Jeffers S, Roman L, Muderspach L, Deauna D, Dikranian A, Muggia F. Extent of prior treatment: only predictor for Taxol-associated neutropenic fever (NF)? Proc ASCO 12:416, 1993.

12. Uziely B, Delaflor-Weiss E, **Russell C**, Leichman CG, Hanisch R, Spicer D, Muggia FM, Press M. Refractory breast cancer treatment with Taxol: Correlations with baseline immunohistochemistry for P-glycoprotein. Proc ECCO, 1993.

13. Uziely B, Delaflor-Weiss E, Lenz HJ, Groshen S, Jeffers S, Watkins K, Danenberg K, **Russell C**, Leichman G, Muggia F, et al. Paclitaxel (taxol) in refractory breast cancer: response correlates with low levels of MDR1 gene expression. Proc ASCO 13:104, 1994.

14. Keren-Rosenberg S, Muggia F, **Russell C**, Parimoo D, Israel V, Rogers M, Jeffers S, Koda R. Estramustine phosphate (EMP) and 3H-paclitaxel (Taxol): A phase I study in women with refractory cancer. Proc ASCO 15:375, 1996.

1. Chalabian J, Formenti S, **Russell C**, Pierce J, Dunnington G. Comprehensive needs assessment of primary care residents’ clinical breast evaluation skills. (meeting abstract and presentation) Soc Surg Onc, 1997.
2. Formenti SC, Skinner K, Silberman H, **Russell CA**, et al. Molecular determinants of response of locally advanced breast cancer to 5-FU and radiation. Proc ASCO 17:536, 1998.
3. Israel V, Garcia AA, **Russell CA**, et al. Phase I study of biweekly paclitaxel and carboplatin +GCSF. Proc ASCO 18:825, 1999.
4. Waisman JR, **Russell C**, Skinner K, et al. Breast cancer mortality after local invasive recurrence in patients with ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Research and Treatment 57(1):abstract 36, 1999.
5. Skinner KA, Silberman H, **Russell C**, Spicer D, et al. Palpability: A poor prognostic finding in patients with invasive breast cancer. Breast Cancer Research and Treatment 57(1):abstract 121, 1999.
6. Silberman H, Skinner K, **Russell, C**, Waisman JR, et al. Infiltrating lobular versus infiltrating ductal carcinoma of the breast. Breast Cancer Research and Treatment 57(1):abstract 224, 1999.
7. Spicer DV, Arzoo KK, Groshen S, Doroshow JH, Gandara DR, Synold T, **Russell C**, et al. Valspodar (V) + Paclitaxel (P) in advanced breast cancer: A California Cancer consortium phase II trial. Proc ASCO 19:696, 2000.
8. Ellis GK, Green SJ, **Russell CA**, Royce ME, Perez, EA, Livingston RB. SWOG 0012, A randomized phase III comparison of standard doxorubicin (A) and Cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral Cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. Proc ASCO 24:LBA537, 2006.
9. **Russell CA**, Stoppler MC, Rothney M, Sing AP. The 21-gene breast cancer assay in small (<1 cm) tumors. Breast Cancer Symposium Abstract 33, 2014.
10. Bello D, **Russell C**, McCullough D, Tierno M, Morrow M. Lymph node status does not predict tumor biology. Podium presentation American Society of Breast Surgeons 2018.